Data / Research funding / Immunization
Immunization: 3,881 NIH awards ($9.4B) to 680 organizations
3,881 NIH awards ($9.4B) in the NIH spending category Immunization, to 680 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 3,881 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| NIAID HIV and Other Infectious Diseases Clinical Research Support Services (CRSS) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $417,904,831 | August 15, 2023 | August 14, 2024 | STROKES, BAMBRA | reporter.nih.gov |
| HIV Vaccines Clinical Trials Network Leadership and Operations Center | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $244,071,463 | June 29, 2006 | November 30, 2027 | COREY, LAWRENCE | reporter.nih.gov |
| HIV Prevention Trials Network Leadership and Operations Center | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $213,590,410 | June 1, 2006 | November 30, 2027 | COHEN, MYRON SCOTT | reporter.nih.gov |
| HIV and Other Infectious Diseases Clinical Research Support Services (CRSS) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $198,645,463 | August 15, 2025 | August 14, 2026 | STOKES, BAMBRA | reporter.nih.gov |
| HIV Vaccine Trials Network Laboratory Center | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $177,480,054 | June 29, 2006 | November 30, 2027 | MCELRATH, MARGARET JULIANA | reporter.nih.gov |
| SDMC: HIV Vaccine Trials Network | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $156,744,802 | June 29, 2006 | November 30, 2027 | GILBERT, PETER B. | reporter.nih.gov |
| CoVPN LOC Cross-Protocol Infrastructure Supplement for GY15 and GY16 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $156,469,927 | March 30, 2022 | March 31, 2022 | COREY, LAWRENCE | reporter.nih.gov |
| Consortium for HIV/AIDS Vaccine Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $145,502,241 | July 1, 2019 | June 30, 2026 | BURTON, DENNIS R. | reporter.nih.gov |
| Induction of protective antibodies for HIV vaccine development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $143,048,158 | July 15, 2019 | June 30, 2026 | HAYNES, BARTON F. | reporter.nih.gov |
| Consortium for Advancing Management and Prevention of Cancer in People with HIV | NIH | National Cancer Institute | 2021 to 2025 | $106,635,299 | August 29, 2006 | August 31, 2030 | SPARANO, JOSEPH A. | reporter.nih.gov |
| NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE: AVIAN INFLUENZA RESEARCH | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $91,354,067 | April 1, 2021 | January 14, 2027 | WEBBY, RICHARD | reporter.nih.gov |
| IMPAACT Leadership Group | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $77,468,129 | December 1, 2024 | November 30, 2027 | NACHMAN, SHARON A | reporter.nih.gov |
| COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $72,825,966 | September 10, 2019 | September 24, 2026 | KRAMMER, FLORIAN | reporter.nih.gov |
| NIAID CLINICAL SITE MONITORING | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $68,539,045 | February 1, 2023 | January 31, 2024 | SMITH, KIMBERLY | reporter.nih.gov |
| Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $63,155,364 | December 5, 2019 | November 30, 2026 | STEPHENS, DAVID S | reporter.nih.gov |
| NIAID Centers of Excellence for Influenza Research and Response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $62,580,113 | April 1, 2021 | September 17, 2026 | GARCIA-SASTRE, ADOLFO | reporter.nih.gov |
| Immune Mechanisms of Protection Against Mycobacterium Tuberculosis Center (IMPAC-TB) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $61,029,344 | September 30, 2019 | March 31, 2027 | URDAHL, KEVIN | reporter.nih.gov |
| CoVPN 5001 - A prospective study of acute immune responses to SARS-CoV-2 infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $57,987,348 | March 21, 2022 | March 31, 2022 | GILBERT, PETER B. | reporter.nih.gov |
| HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals: LC 3 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $54,331,950 | March 18, 2022 | March 31, 2022 | MCELRATH, MARGARET JULIANA | reporter.nih.gov |
| CIVIC: University of Georgia Center for Influenza Vaccine Research in High Risk Populations | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $53,879,677 | September 10, 2019 | September 9, 2026 | ROSS, TED | reporter.nih.gov |
| Collaborative Influenza Vaccine Innovation Centers (CIVICs) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $52,452,735 | September 10, 2019 | September 9, 2026 | MOODY, TONY | reporter.nih.gov |
| DAIDS Quality Assurance, Quality Control and Inspection Readiness Support Services | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $51,529,857 | April 17, 2025 | April 16, 2026 | reporter.nih.gov | |
| CEIRR: CORONAVIRUS RESEARCH ACTIVITIES | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $50,650,417 | April 1, 2021 | September 29, 2026 | HENSLEY, SCOTT | reporter.nih.gov |
| Clinical Research Products Management Center (CRPMC) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $46,852,833 | June 16, 2025 | June 15, 2026 | REMGSAMAI-NHE, CARINA | reporter.nih.gov |
| SUPPORT SERVICES OF THE HIV AIDS CLINICAL TRIAL NETWORKS | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $45,166,816 | November 30, 2022 | November 29, 2025 | DRIVER, BARBARA | reporter.nih.gov |
| Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $44,959,734 | August 13, 2025 | November 30, 2026 | KOTLOFF, KAREN L. | reporter.nih.gov |
| Collaborative Influenza Vaccine Innovation Centers (CIVICs): Component B: Vaccine Manufacturing and Toxicology Core | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $44,296,051 | August 26, 2019 | March 13, 2028 | DENNY, THOMAS | reporter.nih.gov |
| Immune Mechanisms of Protection Against Mycobacterium Tuberculosis Center (IMPAC-TB) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $38,435,039 | September 30, 2019 | September 29, 2026 | FORTUNE, SARAH | reporter.nih.gov |
| Vanderbilt Vaccine and Treatment Evaluation Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $36,564,580 | December 11, 2019 | November 30, 2026 | CREECH, CLARENCE BUDDY | reporter.nih.gov |
| Immune Mechanisms of Protection Against Mycobacterium Tuberculosis Center (IMPAC-TB) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $35,184,139 | August 1, 2021 | July 31, 2026 | COLER, RHEA | reporter.nih.gov |
| Cancer Center Support Grant (CCSG) | NIH | National Cancer Institute | 2021 to 2025 | $35,080,297 | April 1, 1997 | February 28, 2026 | ROBERTS, CHARLES | reporter.nih.gov |
| Production of Aluminum Based Adjuvants | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $34,078,534 | September 20, 2017 | December 31, 2026 | MACK, FRED | reporter.nih.gov |
| Pediatric Adolescent Virus Elimination (PAVE) Martin Delaney Collaboratory | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $30,092,882 | August 16, 2021 | April 30, 2027 | PERSAUD, DEBORAH | reporter.nih.gov |
| DIVINCI: Dissection of Influenza Vaccination and Infection for Childhood Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $30,010,720 | May 2, 2019 | April 30, 2027 | WEBBY, RICHARD JOHN | reporter.nih.gov |
| FOLLOW-UP AND EXTENDED FOLLOW-UP OF PARTICIPANTS | NIH | National Cancer Institute | 2021 to 2025 | $29,487,084 | April 6, 2018 | September 15, 2026 | PORRAS, CAROLINA | reporter.nih.gov |
| Task V15: Development of Assays and Reagents for mpox Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $28,751,383 | September 1, 2022 | April 30, 2026 | RUDGE, THOMAS | reporter.nih.gov |
| REACH: Research Enterprise to Advance a Cure for HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $27,533,114 | August 16, 2021 | April 30, 2027 | JONES, R. BRAD | reporter.nih.gov |
| NIAID Centers of Excellence for Influenza Research and Response (CEIRR): Avian Influenza Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $27,250,171 | April 1, 2021 | January 14, 2027 | LOWEN, ANICE | reporter.nih.gov |
| B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $26,314,793 | June 1, 2022 | May 31, 2027 | HUNTER, ERIC | reporter.nih.gov |
| Impact of the Initial Influenza Exposure on the Quality, Magnitude, Breadth, Potency and Durability of Influenza Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $24,789,202 | May 15, 2019 | April 30, 2027 | STAAT, MARY A | reporter.nih.gov |
| University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $24,477,809 | February 1, 2007 | November 30, 2027 | ERON, JOSEPH J | reporter.nih.gov |
| I4C 2.0: Immunotherapy for Cure | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $23,329,181 | August 16, 2021 | April 30, 2027 | BAROUCH, DAN H. | reporter.nih.gov |
| NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $23,280,590 | August 1, 2021 | January 14, 2027 | PEKOSZ, ANDREW | reporter.nih.gov |
| Vaccine and Treatment Evaluation Units | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $22,981,366 | December 11, 2019 | November 30, 2026 | ROUPHAEL, NADINE GEORGES | reporter.nih.gov |
| MANUFACTURE OF CLINICAL GRADE EPSTEIN-BARR VIRUS VACCINE | NIH | National Cancer Institute | 2023 to 2025 | $22,579,077 | September 22, 2025 | September 21, 2027 | reporter.nih.gov | |
| SOSIP-NP/mRNA combination for novel preventive and therapeutic HIV-1 vaccine regimens | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $21,986,953 | September 2, 2022 | June 30, 2027 | WILLIAMS, WILTON B | reporter.nih.gov |
| NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,625,203 | April 1, 2021 | September 14, 2027 | TOMPKINS, S. MARK | reporter.nih.gov |
| UZ-UCSF CTU | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,624,239 | September 9, 2025 | November 30, 2027 | CHIRENJE, ZVAVAHERA MIKE | reporter.nih.gov |
| UCLA AIDS Prevention and Treatment Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,546,764 | February 1, 2007 | November 30, 2027 | LANDOVITZ, RAPHAEL J | reporter.nih.gov |
| Boston HIV CTU | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,445,869 | January 15, 2007 | November 30, 2027 | KURITZKES, DANIEL R. | reporter.nih.gov |
| Vaccine and Treatment Evaluation Unit at Saint Louis University | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,219,564 | December 11, 2019 | November 30, 2026 | HOFT, DANIEL F. | reporter.nih.gov |
| New Mexico IDeA Networks of Biomedical Research Excellence (INBRE) | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $20,744,885 | September 30, 2001 | March 31, 2029 | LUSETTI, SHELLEY | reporter.nih.gov |
| COVID-19: External Quality Assurance Program Oversight Laboratory (EQAPOL) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $20,632,183 | September 30, 2023 | September 29, 2024 | DENNY, THOMAS | reporter.nih.gov |
| Alzheimer's Prevention Initiative ADAD Colombia Trial Program | NIH | National Institute on Aging | 2024 to 2025 | $20,406,409 | September 1, 2024 | August 31, 2029 | ALEXANDER, ROBERT C | reporter.nih.gov |
| Vaccine and Treatment Evaluation Units (VTEU) 24-0003 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $19,949,752 | December 11, 2019 | November 30, 2026 | EL SAHLY, HANA M | reporter.nih.gov |
| Collaborative Influenza Vaccine Innovation Centers (CIVICs): Component C: Clinical Core | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $19,720,676 | September 16, 2019 | September 15, 2026 | FRANKENFIELD, JILL | reporter.nih.gov |
| ADJUVANT COMPARISON AND CHARACTERIZATION | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $19,155,153 | September 1, 2022 | August 31, 2027 | PULENDRAN, BALI | reporter.nih.gov |
| ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $18,205,751 | September 19, 2022 | September 18, 2026 | SAUNDERS, KEVIN | reporter.nih.gov |
| Cancer Center Support Grant P30 | NIH | National Cancer Institute | 2021 to 2025 | $17,994,069 | July 1, 2002 | June 30, 2026 | LARA, PRIMO N. | reporter.nih.gov |
| Immunologic strategies to prevent congenital cytomegalovirus transmission and disease in rhesus monkeys | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $17,214,484 | July 24, 2019 | May 31, 2029 | PERMAR, SALLIE R. | reporter.nih.gov |
| Emory-CDC CTU | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,972,899 | December 1, 2024 | November 30, 2027 | KELLEY, COLLEEN F | reporter.nih.gov |
| Collaborative Influenza Vaccine Innovation Centers (CIVICs): Component C: Clinical Core | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,914,921 | September 16, 2019 | September 30, 2026 | BERES, WENDELL | reporter.nih.gov |
| University of Pennsylvania HIV Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,198,927 | February 1, 2007 | November 30, 2027 | FRANK, IAN | reporter.nih.gov |
| DEVELOPMENT OF A VACCINE CANDIDATE FOR CORONAVIRUSES | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $15,898,493 | June 1, 2023 | May 31, 2026 | KRAMMER, FLORIAN | reporter.nih.gov |
| PERU Clinical Trial Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,506,525 | December 1, 2024 | November 30, 2027 | SANCHEZ, JORGE LUIS | reporter.nih.gov |
| Targeting Inflammation and Alloimmunity in Lung Transplant Recipients With Clazakizumab | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,471,597 | September 14, 2021 | June 30, 2028 | MADSEN, JOREN C | reporter.nih.gov |
| NIAID Influenza Data Processing and Communication Center: Universal Influenza Vaccine Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,386,477 | April 1, 2021 | March 31, 2026 | BOUR, STEPHAN | reporter.nih.gov |
| Immune signatures of vaccine responses in vulnerable populations | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,275,325 | July 12, 2010 | April 30, 2028 | MONTGOMERY, RUTH R | reporter.nih.gov |
| University of Washington Vaccine and Treatment Evaluation Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,173,751 | December 11, 2019 | November 30, 2026 | WALD, ANNA | reporter.nih.gov |
| FSH - an Aging Hormone? | NIH | National Institute on Aging | 2021 to 2025 | $15,166,862 | February 1, 2019 | April 30, 2029 | ZAIDI, MONE | reporter.nih.gov |
| A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-N-methyl-D-aspartate receptor (NMDAR) Encephalitis and Assess Markers of Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $15,144,108 | September 15, 2021 | August 31, 2027 | CLARDY, STACEY LYNN | reporter.nih.gov |
| PHRU-Setshaba Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,110,381 | December 1, 2024 | November 30, 2027 | GRAY, GLENDA E | reporter.nih.gov |
| Consolidated Basic Cancer Research Program | NIH | National Cancer Institute | 2021 to 2025 | $14,936,465 | April 1, 1997 | February 28, 2026 | ALTIERI, DARIO C | reporter.nih.gov |
| HIPC Data Coordinating Center | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $14,760,228 | April 13, 2022 | March 31, 2027 | PETERS, BJOERN | reporter.nih.gov |
| University of Rochester Vaccine and Treatment Evaluation Unit (VTEU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $14,263,529 | December 11, 2019 | November 30, 2026 | FALSEY, ANN R | reporter.nih.gov |
| Kaiser Washington Vaccine and Treatment Evaluation Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $14,173,633 | December 11, 2019 | November 30, 2026 | JACKSON, LISA A | reporter.nih.gov |
| Simian Vaccine Evaluation Unit: Maintenance of Nonhuman Primates | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $14,042,495 | April 1, 2020 | March 31, 2027 | AYE, PYONE | reporter.nih.gov |
| Simian Vaccine Evaluation Unit: Maintenance of Nonhuman Primates | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,765,907 | April 1, 2020 | March 31, 2027 | VILLINGER, FRANCOIS | reporter.nih.gov |
| HIV/AIDS Clinical Trials Units University of Cape Town CTU 2020 to 2027 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,518,599 | April 1, 2007 | November 30, 2027 | BEKKER, LINDA-GAIL | reporter.nih.gov |
| Protective immunity following dengue virus natural infections and vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,429,941 | July 29, 2015 | July 31, 2030 | HARRIS, EVA | reporter.nih.gov |
| Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,340,237 | April 10, 2020 | November 30, 2026 | MULLIGAN, MARK JOSEPH | reporter.nih.gov |
| IND-enabling Studies in Support of First in Human Safety Studies of a Novel Anti-Nicotine Human Monoclonal Antibody | NIH | National Institute on Drug Abuse | 2023 to 2025 | $13,125,765 | May 1, 2023 | April 30, 2027 | KALNIK, MATTHEW W | reporter.nih.gov |
| Pitt-Ohio State Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,065,770 | February 1, 2007 | November 30, 2027 | RIDDLER, SHARON | reporter.nih.gov |
| Understanding Influenza and SARS-CoV-2 vaccine responses, in vivo and in vitro | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,884,300 | September 1, 2003 | April 30, 2029 | DAVIS, MARK MORRIS | reporter.nih.gov |
| HEALTH Center for Addictions Research and Cancer Prevention | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2024 | $12,882,144 | September 8, 2020 | April 30, 2026 | BEECH, BETTINA M. | reporter.nih.gov |
| Vanderbilt HIV Clinical Trials Unit (CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,733,650 | February 1, 2007 | November 30, 2027 | HAAS, DAVID W | reporter.nih.gov |
| Case Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,725,521 | December 1, 2024 | November 30, 2027 | YENDEWA, GEORGE | reporter.nih.gov |
| Respiratory pathogen-specific T cell signatures following vaccination, natural infection, and treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,580,221 | June 1, 2025 | May 31, 2027 | SETTE, ALESSANDRO | reporter.nih.gov |
| CURE CTU | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,461,433 | January 1, 2007 | November 30, 2027 | SPECTOR, STEPHEN A | reporter.nih.gov |
| Columbia Collaborative HIV/AIDS Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,286,513 | February 1, 2007 | November 30, 2027 | SOBIESZCZYK, MAGDALENA ELZBIETA | reporter.nih.gov |
| Cincinnati Children's Hospital Medical Center Vaccine and Treatment Evaluation Units (UM1 Clinical Trial Required) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,115,898 | December 11, 2019 | November 30, 2026 | FRENCK, ROBERT WILSON | reporter.nih.gov |
| Center for Redox Biology and Cardiovascular Disease | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $12,065,347 | February 1, 2018 | June 30, 2028 | KEVIL, CHRISTOPHER G | reporter.nih.gov |
| PDB MANAGEMENT BY THE RESEARCH COLLABORATORY FOR STRUCTURAL BIOINFORMATICS | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $12,006,722 | August 1, 2019 | September 18, 2024 | BURLEY, STEPHEN K | reporter.nih.gov |
| Human anti-viral immune responses in tissues and circulation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,930,741 | January 1, 2017 | February 28, 2027 | FARBER, DONNA L. | reporter.nih.gov |
| Targeting the B Cell Response to Treat Antibody-Mediated Rejection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,789,092 | August 20, 2021 | May 31, 2028 | KNECHTLE, STUART JOHNSTON | reporter.nih.gov |
| Durable Alteration of the Human Immune system after Infection or Immunotherapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,785,761 | June 8, 2009 | May 31, 2029 | CHUNG, RAYMOND T | reporter.nih.gov |
| Task A71: Comprehensive In Vivo Screening of Viral Pathogens of Pandemic Potential | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,745,278 | July 18, 2022 | July 17, 2025 | MORREY, JOHN | reporter.nih.gov |
| Development of an Optimized Adjuvanted TB Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $11,645,061 | September 30, 2021 | September 30, 2025 | EVANS, JAY | reporter.nih.gov |
| Preclinical and Translational Vaccine Development for HIV and Other Candidate Agents (PTVDS) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $11,597,222 | December 1, 2024 | November 30, 2025 | DENNY, TOM | reporter.nih.gov |
| Reagent Resource Support Program for AIDS Vaccine Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $11,522,629 | April 8, 2018 | April 7, 2025 | FREMONT, VALERIE | reporter.nih.gov |
| KwaZulu-Natal Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,302,268 | December 1, 2024 | November 30, 2027 | ABDOOL KARIM, QUARRAISHA | reporter.nih.gov |
| Advancing Transplantation Outcomes in Children | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,293,854 | July 1, 2025 | June 30, 2028 | BRISCOE, DAVID M. | reporter.nih.gov |
| Advanced Development of Vaccine Candidates for Antibiotic Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,268,155 | September 1, 2020 | March 31, 2027 | MALINOWSKI, FRANK | reporter.nih.gov |
| The Johns Hopkins University-Blantyre Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,246,510 | February 15, 2007 | November 30, 2027 | TAHA, TAHA E | reporter.nih.gov |
| Administrative Supplement for the NCI P30 CCSG to extend partnerships with comprehensive cancer control coalitions to study implementation of evidence-based cancer control interventions | NIH | National Cancer Institute | 2021 | $11,079,774 | January 1, 1997 | March 31, 2022 | LYNCH, THOMAS JAMES | reporter.nih.gov |
| Vaccines for fentanyl and its derivatives: A strategy to reduce illicit use and overdose | NIH | National Institute on Drug Abuse | 2022 to 2024 | $11,034,562 | February 1, 2019 | July 31, 2025 | PRAVETONI, MARCO | reporter.nih.gov |
| Advancing Vaccine Adjuvant Research for Tuberculosis (TB) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $10,964,476 | September 30, 2022 | September 29, 2027 | BRITTON, WARWICK | reporter.nih.gov |
| Johns Hopkins University Baltimore India Clinical Trail Unit (JHUBI CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,947,708 | February 5, 2007 | November 30, 2027 | GUPTA, AMITA | reporter.nih.gov |
| Advanced Development of a Universal Influenza Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,853,574 | September 9, 2019 | April 24, 2025 | LOCHER, CHRISTOPHER | reporter.nih.gov |
| Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,650,296 | September 9, 2019 | October 31, 2025 | CASPER, COREY | reporter.nih.gov |
| Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA. | NIH | National Institute on Aging | 2022 to 2025 | $10,320,460 | February 15, 2022 | January 31, 2027 | AGADJANYAN, MICHAEL G | reporter.nih.gov |
| Nonhuman Primate (NHP) Core Functional Genomics Laboratory for AIDS Vaccine Research and Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,303,422 | July 1, 2019 | June 30, 2020 | GALE, MICHAEL | reporter.nih.gov |
| ADJUVANT COMPARISON AND CHARACTERIZATION | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $10,234,165 | September 1, 2022 | January 1, 2027 | FELGNER, PHILIP | reporter.nih.gov |
| University of Rochester HIV/AIDS Clinical Trials Unit Administrative Supplement | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,156,163 | August 26, 2025 | November 30, 2027 | KEEFER, MICHAEL C | reporter.nih.gov |
| Nonhuman Primate Core Humoral Immunology Laboratory for AIDS Vaccine Research and Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,129,006 | March 30, 2024 | March 29, 2025 | SHEN, SHAUNNA | reporter.nih.gov |
| Thailand HIV/AIDS and Infectious Disease Clinical Trials Unit (THAI CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,070,868 | March 15, 2007 | November 30, 2027 | SUPPARATPINYO, KHUANCHAI | reporter.nih.gov |
| Advanced Development of a Multivalent Vaccine Candidate for Lassa Fever | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,931,387 | September 1, 2017 | January 31, 2027 | SCHNELL, MATTHIAS JOHANNES | reporter.nih.gov |
| The Military HIV Research Program (MHRP) Clinical Trial Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,910,676 | December 10, 2013 | November 30, 2027 | ROBB, MERLIN L | reporter.nih.gov |
| The Johns Hopkins University - Uganda Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,910,249 | February 5, 2007 | November 30, 2027 | FOWLER, MARY GLENN | reporter.nih.gov |
| Viral Immunity and VAccination (VIVA) Human Immunology Project Consortium (HIPC) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $9,862,919 | March 22, 2022 | February 28, 2027 | FERNANDEZ-SESMA, ANA | reporter.nih.gov |
| Expanded SPF Rhesus Macaque Breeding Colony for AIDS Research | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $9,705,199 | August 1, 2016 | August 31, 2028 | BOHM, RUDOLF PAUL | reporter.nih.gov |
| Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant candidates (COLT) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $9,640,870 | August 26, 2021 | September 30, 2024 | LIMAYE, ABHIJIT PRAKASH | reporter.nih.gov |
| DEVELOPMENT OF UM-1098: A NOVEL SYNTHETIC TH17 INDUCING ADJUVANT AND DELIVERY SYSTEM | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $9,566,206 | September 30, 2023 | September 29, 2026 | EVANS, JAY | reporter.nih.gov |
| University of Washington Arboviral Research Network (UWARN) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $9,499,281 | May 22, 2020 | June 5, 2025 | VAN VOORHIS, WESLEY C | reporter.nih.gov |
| Early in vivo Expressed Antigens and their Role in Virulence, Immune Response, and Vaccines for Coccidioidomycosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $9,218,182 | August 24, 2022 | July 31, 2027 | BARKER, BRIDGET MARIE | reporter.nih.gov |
| A-Z Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $8,989,738 | February 1, 2007 | November 30, 2027 | GOEPFERT, PAUL A. | reporter.nih.gov |
| Task V34: Master Cell Banks Manufacturing for Next Generation SARS-CoV-2 Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $8,647,922 | May 15, 2018 | May 14, 2028 | TRUSHEIM, HEIDI | reporter.nih.gov |
| Simian Vaccine Evaluation Unit: Core Activities - Administrative and Technical Support | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $8,478,988 | April 1, 2020 | March 31, 2027 | LEWIS, MARK | reporter.nih.gov |
| San Francisco Bay Clinical Trials Unit (CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $8,314,128 | March 2, 2007 | November 30, 2027 | BUCHBINDER, SUSAN | reporter.nih.gov |
| A Humanized Monoclonal FSH Blocking Antibody for Alzheimer's Disease | NIH | National Institute on Aging | 2021 to 2025 | $8,293,749 | September 30, 2021 | August 31, 2026 | ZAIDI, MONE | reporter.nih.gov |
| Consortia for Innovative AIDS Research in Nonhuman Primates | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $8,268,168 | May 1, 2016 | April 30, 2022 | BAROUCH, DAN H. | reporter.nih.gov |
| Development of a monoclonal antibody to reverse overdose from fentanyl and its analogs: from manufacturing to clinical trials | NIH | National Institute on Drug Abuse | 2022 | $8,267,350 | September 30, 2022 | September 29, 2025 | PRAVETONI, MARCO | reporter.nih.gov |
| Manufacturing of Drug Product, Dual Aβ/tau Vaccine for Clinical Trials | NIH | National Institute on Aging | 2021 to 2023 | $8,244,109 | February 1, 2019 | January 31, 2025 | AGADJANYAN, MICHAEL G | reporter.nih.gov |
| The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $8,239,326 | January 15, 2008 | November 30, 2027 | GRINSZTEJN, BEATRIZ | reporter.nih.gov |
| A deep longitudinal analysis of next generation influenza vaccines in older adults | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $8,127,184 | January 1, 2022 | December 31, 2026 | UCAR, DUYGU | reporter.nih.gov |
| cGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $8,013,603 | August 30, 2022 | August 29, 2030 | HASSELL, THOMAS | reporter.nih.gov |
| External Quality Assurance Program Oversight Laboratory (EQAPOL) | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $7,902,910 | September 30, 2024 | September 29, 2031 | DENNY, THOMAS | reporter.nih.gov |
| Advanced Development and Clinical Evaluation of an Entamoeba Histolytica Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $7,788,182 | September 21, 2018 | November 22, 2025 | FOX, CHRISTOPHER | reporter.nih.gov |
| Integrating innate and adaptive pathways in vaccine responses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $7,762,589 | April 1, 2014 | March 31, 2024 | RAVETCH, JEFFREY VICTOR | reporter.nih.gov |
| Seattle Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $7,698,581 | February 1, 2007 | November 30, 2027 | MCELRATH, MARGARET JULIANA | reporter.nih.gov |
| University of Arizona Cancer Prevention Clinical Trials Network | NIH | National Cancer Institute | 2021 to 2025 | $7,572,043 | August 16, 2019 | July 31, 2031 | THOMPSON, PATRICIA ANN | reporter.nih.gov |
| Ad26 Based Therapeutic Vaccines for HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $7,518,476 | May 12, 2020 | April 30, 2027 | BAROUCH, DAN H. | reporter.nih.gov |
| Advanced Development of Vaccines for Filoviruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $7,417,867 | July 21, 2020 | December 31, 2026 | ELDRIDGE, JOHN | reporter.nih.gov |
| Collaborative Influenza Vaccine Innovation Centers STATISTICAL, DATA MANAGEMENT AND COORDINATION CENTER (SDMCC) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $7,400,390 | September 30, 2025 | September 29, 2026 | BOUR, STEPHAN | reporter.nih.gov |
| Administrative Supplements for NIAID Regional Biocontainment Laboratories (RBL) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $7,369,853 | September 23, 2021 | February 28, 2025 | ALEM, FARHANG | reporter.nih.gov |
| DEVELOPMENT OF VACCINES FOR INFLUENZA USING AN IMMUNO-MODULATOR ADJUVANT AND MULTI-PLATFORM APPROACH | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $7,281,050 | September 30, 2023 | September 29, 2028 | EL-KAMMASH, BRUXANNE | reporter.nih.gov |
| Adjuvant Development of the TLR4 Ligand BECC470s For Use in Influenza, S. aureus, and P. aeruginosa Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $7,143,498 | September 30, 2023 | September 29, 2028 | SORENSON, GREGORY | reporter.nih.gov |
| iCAN PREVENT: MD Anderson International Cancer Prevention Clinical Trials Consortium | NIH | National Cancer Institute | 2021 to 2025 | $7,046,172 | August 15, 2019 | July 31, 2031 | VILAR SANCHEZ, EDUARDO | reporter.nih.gov |
| TASK ORDER B-15: Model Development and Medical Countermeasure Evaluation | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $7,029,612 | October 24, 2022 | October 1, 2023 | GRIFFITHS, ANTHONY | reporter.nih.gov |
| ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $6,937,118 | September 30, 2023 | September 29, 2026 | COLLINS, NICOLAS | reporter.nih.gov |
| Molecular and Immunologic Analysis of the Pathobiology of Human Anthrax | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $6,892,629 | September 15, 2004 | August 31, 2025 | FARRIS, A DARISE | reporter.nih.gov |
| Native-like Envelope Trimer Therapeutic Vaccination for Induction of Broadly Neutralizing Antibodies to Facilitate HIV Functional Cure | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,813,637 | April 14, 2020 | July 31, 2027 | RIDDLER, SHARON | reporter.nih.gov |
| Development of a COVID-19 Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $6,733,518 | September 1, 2020 | October 31, 2023 | REED, STEVEN | reporter.nih.gov |
| Lyme Disease: B cell epitope discovery and mechanisms of antibody protection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $6,722,146 | September 16, 2019 | September 15, 2024 | MANTIS, NICHOLAS J. | reporter.nih.gov |
| B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection - Administrative Supplement | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $6,714,942 | June 1, 2016 | May 31, 2022 | HUNTER, ERIC | reporter.nih.gov |
| Making antibody generation rapid, scalable, and democratic through machine learning and continuous evolution | NIH | National Cancer Institute | 2021 to 2024 | $6,686,758 | September 10, 2020 | August 31, 2025 | LIU, CHANG C | reporter.nih.gov |
| Aurum Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,678,965 | December 1, 2020 | November 30, 2027 | CHURCHYARD, GAVIN JOHN | reporter.nih.gov |
| A Global Syphilis Vaccine Targeting Outer Membrane Proteins of Treponema pallidum. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $6,678,063 | May 1, 2019 | April 30, 2025 | RADOLF, JUSTIN D | reporter.nih.gov |
| Administrative Supplement for Upgrading the University of Pittsburgh Regional Biocontainment Laboratory within The Center for Vaccine Research | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $6,659,737 | August 22, 2022 | February 28, 2025 | DUPREX, WILLIAM PAUL | reporter.nih.gov |
| B Cell Epitope Discovery and Mechanisms of Antibody Protection: Responses to Dengue 4, Powassan, Chikungunya, and Venezuelan Equine Encephalitis Viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $6,634,396 | September 16, 2023 | September 15, 2024 | FREMONT, DAVED | reporter.nih.gov |
| Advanced Development of Vaccine Candidates for Biodefense and Emerging Antibiotic-Resistant Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $6,612,767 | September 21, 2022 | January 18, 2026 | KRUISWIJK, CORINE | reporter.nih.gov |
| Leveraging an ongoing longitudinal study of influenza vaccination to define immune signatures of response and risk of infection in older adults >75 | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $6,605,926 | December 9, 2021 | November 30, 2026 | LENG, SEAN XIAO | reporter.nih.gov |
| California-Mexico-Puerto Rico Partnership (CAMPO) Center for Prevention of HPV-related Cancer in HIV+ Populations | NIH | National Cancer Institute | 2021 to 2025 | $6,605,241 | September 12, 2019 | July 31, 2026 | PALEFSKY, JOEL MICHAEL | reporter.nih.gov |
| Facility and Building System Upgrades Support for the Howard T. Ricketts Biocontainment Laboratory | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $6,593,067 | September 16, 2021 | February 28, 2025 | ADAMS, ERIN JUNE | reporter.nih.gov |
| Advanced Development of Vaccine Candidates for Biodefense and Emerging Antibiotic-Resistant Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $6,592,393 | September 23, 2022 | July 22, 2026 | NORTON, ELIZABETH | reporter.nih.gov |
| Comparative Modeling to Inform Cervical Cancer Control Policies | NIH | National Cancer Institute | 2021 to 2024 | $6,568,988 | September 8, 2020 | August 31, 2025 | KIM, JANE JOOYUN | reporter.nih.gov |
| Task A68: Screening Vaccine (and Other Biologics) Platform Technologies using Coronavirus Mouse Immunogenicity as a Model System | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,550,363 | May 23, 2022 | September 30, 2026 | GRAHAM, RACHEL | reporter.nih.gov |
| Stellenbosch University Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,524,563 | April 15, 2007 | November 30, 2027 | HESSELING, ANNEKE CATHARINA | reporter.nih.gov |
| Small-molecule activators of STING-signaling as novel adjuvants for flavivirus vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $6,461,817 | September 30, 2019 | September 29, 2024 | NELSON, JAY | reporter.nih.gov |
| University of Washington (UW) Sexually Transmitted Infections (STI) Cooperative Research Center (CRC) - Syphilis Vaccine to Protect against Local and Disseminated T. pallidum Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $6,406,743 | August 1, 2019 | July 31, 2025 | WALD, ANNA | reporter.nih.gov |
| Harnessing B cells for TB vaccine development to improve therapy of TB and TB-HIV coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,398,428 | July 1, 2021 | June 30, 2027 | GENGENBACHER, MARTIN ALFONS | reporter.nih.gov |
| DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $6,359,752 | September 30, 2023 | September 29, 2028 | LAPEK, JENNIFER | reporter.nih.gov |
| Biologically informed design of CD8+ T cell-dependent pre-erythrocytic stage malaria vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,330,175 | February 4, 2021 | January 31, 2026 | KAPPE, STEFAN HI | reporter.nih.gov |
| DUAL AFFINITY RE-TARGETING (DART) MOLECULES FOR HIV-1 SUPPRESSION | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $6,287,950 | September 15, 2015 | July 14, 2023 | NORDSTROM, JEFFREY | reporter.nih.gov |
| BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERSTASK ORDER TITLE: VACCINES AGAINST FUSOBACTERIUM FOR FAP-AND LYNCH SYNDROME-ASSOCIA | NIH | National Cancer Institute | 2022 to 2024 | $6,227,249 | June 15, 2022 | May 15, 2025 | CLAPPER, MARGIE L. | reporter.nih.gov |
| Southwest Clinical Trials Node: Clinical Research and Practice to Address Substance Use in Diverse, Rural, and Underserved Populations | NIH | National Institute on Drug Abuse | 2021 to 2025 | $6,192,905 | June 1, 2019 | February 29, 2032 | PAGE, KIMBERLY | reporter.nih.gov |
| A Clinical Trial of Three Broadly Neutralizing Antibodies and Analytic Treatment Interruption in Early-Treated Children in Botswana | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $6,096,179 | September 5, 2023 | June 30, 2028 | SHAPIRO, ROGER L | reporter.nih.gov |
| Design and testing of immunogens to elicit 10E8-like broadly neutralizing antibodies against HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,090,710 | July 8, 2019 | August 31, 2029 | SCHIFFNER, TORBEN | reporter.nih.gov |
| TO IDENTIFY NOVEL ADJUVANT CANDIDATES THAT CAN BE USED TO AUGMENT THE EFFICACY OF HUMAN VACCINES. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,022,974 | September 30, 2019 | April 30, 2026 | CARSON, DENNIS | reporter.nih.gov |
| Partnership for Prevention of HPV-Associated Cancers in People Living with HIV: Brazil, Mexico, and Puerto Rico | NIH | National Cancer Institute | 2021 to 2025 | $5,948,066 | September 20, 2019 | July 31, 2026 | ELLSWORTH, GRANT B. | reporter.nih.gov |
| B-CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,936,710 | September 16, 2019 | August 31, 2025 | CROWE, JAMES E | reporter.nih.gov |
| Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,933,702 | April 8, 2021 | March 31, 2027 | SIM, B. KIM LEE | reporter.nih.gov |
| DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $5,907,864 | September 30, 2023 | September 29, 2028 | BURKHART, DAVID | reporter.nih.gov |
| Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant candidates (COLT) | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $5,882,740 | August 26, 2021 | May 31, 2028 | LIMAYE, ABHIJIT PRAKASH | reporter.nih.gov |
| Discovery of adjuvants via novel modulation of innate immune pathways for vaccines against influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,841,904 | September 30, 2019 | April 30, 2026 | ESSER-KAHN, AARON | reporter.nih.gov |
| Drivers of individual variation in influenza vaccine response and protection from infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,827,282 | July 14, 2022 | June 30, 2027 | COBEY, SARAH | reporter.nih.gov |
| The Role of B cells in the Origin and Progression of Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $5,776,308 | May 1, 2019 | April 30, 2027 | HAUSER, STEPHEN L | reporter.nih.gov |
| Cancer Immune Monitoring and Analysis Center | NIH | National Cancer Institute | 2023 to 2025 | $5,746,876 | September 30, 2017 | June 30, 2028 | WU, CATHERINE JU-YING | reporter.nih.gov |
| Rational design and efficacy testing of vaccines against HCV | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,737,237 | May 5, 2022 | April 30, 2027 | FUERST, THOMAS R | reporter.nih.gov |
| Computational models of naturally acquired immunity to falciparum malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,666,873 | April 1, 2020 | March 31, 2026 | GREENHOUSE, BRYAN R | reporter.nih.gov |
| Small-molecule inducers of the cGAS/STING pathway as novel adjuvants for flu vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $5,636,289 | September 30, 2019 | September 29, 2024 | ADOLFO, GARCIA-SASTRE | reporter.nih.gov |
| Nonhuman Primate (NHP) Core Cellular Immunology Laboratory for AIDS Vaccine Research Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $5,634,048 | June 1, 2023 | May 31, 2024 | KAUR, AMITINDER | reporter.nih.gov |
| Task V02: Manufacture of Influenza for Human Challenge Clinical Trials | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,587,695 | May 15, 2018 | May 31, 2026 | HASSEL, THOMAS | reporter.nih.gov |
| Cervical, Anal & Oral HPV Persistence/Adolescent Girls | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,549,203 | May 15, 2007 | January 31, 2028 | DIAZ, ANGELA | reporter.nih.gov |
| Inter-regional study of transmission, adaptation and pathogenesis of viruses with pandemic potential in Southeast Asia and West/Central Africa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,526,401 | July 17, 2020 | June 5, 2025 | SAKUNTABHAI, ANAVAJ | reporter.nih.gov |
| Advanced Development of Vaccines for Influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,495,941 | September 9, 2019 | May 31, 2027 | STAERZ, UWE | reporter.nih.gov |
| Small-molecule adjuvants testing pipeline (Influenza) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $5,486,225 | September 30, 2019 | September 29, 2024 | LEVY, OFER | reporter.nih.gov |
| Molecular mechanisms of antibody-mediated immunotherapies | NIH | National Cancer Institute | 2021 to 2025 | $5,461,259 | April 1, 2016 | August 31, 2029 | RAVETCH, JEFFREY VICTOR | reporter.nih.gov |
| Cellular Immunology Core Laboratory | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $5,413,068 | June 1, 2025 | May 31, 2026 | KAUR, AMITINDER | reporter.nih.gov |
| Developing computational models to predict the immune response to B. pertussis booster vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,401,756 | March 10, 2020 | February 28, 2025 | PETERS, BJOERN | reporter.nih.gov |
| Task V31: Process Development for a Panfungal Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,346,445 | January 20, 2023 | July 30, 2025 | FOUTS, TIM | reporter.nih.gov |
| A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in Botswana | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,339,746 | February 20, 2018 | January 31, 2026 | SHAPIRO, ROGER L | reporter.nih.gov |
| FDA approved IND 29644: Multicenter Phase 1 Trial to Evaluate Safety and Immunogenicity of Preventive Tau Vaccine, AV-1980R/A, in cognitively unimpaired preclinical AD participants. | NIH | National Institute on Aging | 2025 | $5,308,961 | August 1, 2025 | July 31, 2030 | AGADJANYAN, MICHAEL G | reporter.nih.gov |
| Optimization and testing of anti-methamphetamine antibody therapy to support pivotal clinical trials and commercialization | NIH | National Institute on Drug Abuse | 2021 to 2022 | $5,281,643 | May 1, 2020 | February 29, 2024 | STEVENS, MISTY WARD | reporter.nih.gov |
| Adjuvant Comparison and Characterization of Peanut Antigen | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,238,569 | September 25, 2025 | September 24, 2026 | STAATS, HERMAN | reporter.nih.gov |
| Understanding and Mimicking TCR Recognition with Therapeutic Monoclonal Antibodies. | NIH | National Cancer Institute | 2021 to 2025 | $5,214,422 | August 14, 2020 | July 31, 2027 | SCHEINBERG, DAVID A | reporter.nih.gov |
| Advancement of a poxvirus antiviral | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,192,454 | March 12, 2020 | August 31, 2029 | CONNOR, JOHN H | reporter.nih.gov |
| HIV-1 Q23.17 Env: Engineering a novel immunogen to elicit broadly neutralizing antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,173,076 | June 23, 2021 | May 31, 2026 | SHAW, GEORGE M | reporter.nih.gov |
| Development of vaccination strategies to elicit broadly protective immunity against influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,165,779 | June 18, 2019 | June 30, 2029 | RAVETCH, JEFFREY VICTOR | reporter.nih.gov |
| High-throughput proteomics using submicroliter amounts of plasma for comprehensive assessment of the immune status | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,147,391 | April 9, 2020 | March 31, 2026 | STEEN, HANNO | reporter.nih.gov |
| Comparison of High vs. Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant Recipients | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $5,116,475 | June 9, 2023 | March 31, 2028 | HALASA, NATASHA BASSAM | reporter.nih.gov |
| Immune Cells and Secretory Pathways Leading to Human Systemic Autoimmunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,112,288 | May 1, 2019 | April 30, 2029 | PASCUAL, MARIA VIRGINIA | reporter.nih.gov |
| Rapid structure-based software to enhance antibody affinity and developability for high-throughput screening: Aiming toward total in silico design of antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,047,322 | May 1, 2020 | April 30, 2027 | BLATTNER, FREDERICK R | reporter.nih.gov |
| Development of Therapeutic Candidates for Biodefense, Infections and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $5,018,496 | July 5, 2023 | May 31, 2028 | VOIGT, EMILY | reporter.nih.gov |
| Task 12: Sexually Transmitted Infections Clinical Trials Group: Phase 2 Clinical Trial to Evaluate a Vaccine Candidate for Neisseria Gonorrhoeae | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,969,800 | September 6, 2019 | June 30, 2026 | HOOK, EDWARD | reporter.nih.gov |
| Evaluation of an OMV-adjuvanted Chimeritrope Vaccine against Lyme Disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $4,961,891 | September 30, 2018 | September 29, 2023 | MORICI, LISA | reporter.nih.gov |
| The "Dynamics of the immune responses to repeat influenza vaccination exposures" (DRIVE) Study | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,955,723 | September 11, 2020 | June 30, 2026 | COBEY, SARAH | reporter.nih.gov |
| Fine Mechanisms of Adaptive NK Cell Formation Against HIV and SIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,922,128 | August 20, 2021 | July 31, 2027 | REEVES, ROGER KEITH | reporter.nih.gov |
| Mechanisms of human papillomavirus entry | NIH | National Cancer Institute | 2021 to 2025 | $4,915,530 | August 17, 2020 | July 31, 2027 | DIMAIO, DANIEL C. | reporter.nih.gov |
| Preclinical development of a vaccine for Nipah virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,912,518 | March 11, 2021 | February 28, 2027 | GEISBERT, THOMAS WILLIAM | reporter.nih.gov |
| Antigen recognition and activation of HIV-specific B cell antigen receptors | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,911,145 | March 20, 2019 | July 31, 2029 | ALAM, S. MUNIR | reporter.nih.gov |
| Living in the post-Zika world: Impact of interactions between dengue and Zika viruses on diagnostics, antibody dynamics, and correlates of disease risk | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,905,886 | July 13, 2021 | April 30, 2027 | HARRIS, EVA | reporter.nih.gov |
| Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $4,889,710 | June 7, 2024 | June 1, 2026 | BRUYETTE, DAVID | reporter.nih.gov |
| Large Scale T Cell Epitope Discovery:Global identification of epitopes derived from Zika (ZIKV), Chikungunya (CHIKV) viruses following natural infection and vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,881,220 | September 30, 2019 | September 29, 2024 | MITCHELL, MAYA | reporter.nih.gov |
| Structure based design of trimer interface epitope focused universal influenza vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,864,362 | March 12, 2020 | February 28, 2025 | CROWE, JAMES E | reporter.nih.gov |
| Strategically Engineered Multi-Antigen KSHV Vaccine: Integrating Humoral and Cellular Immunity for Effective Protection | NIH | National Cancer Institute | 2025 | $4,857,475 | August 7, 2025 | July 31, 2029 | WU, TING-TING | reporter.nih.gov |
| Accelerating discovery of an efficacious Plasmodium vivax multivalent multi-stage vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,835,728 | December 1, 2020 | November 30, 2026 | ADAMS, JOHN H | reporter.nih.gov |
| HIV-1 Fusion Peptide-directed Vaccine Design Using Virus-like Particles | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,825,382 | March 1, 2021 | February 28, 2027 | KONG, RUI | reporter.nih.gov |
| Autonomously deploying, co-evolving SARS-CoV-2 antiviral: a new paradigm for pandemic prevention | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,817,583 | September 24, 2021 | August 31, 2024 | RODICK, ROBERT | reporter.nih.gov |
| Novel Stem Cell Immunotherapy for MDR-Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,800,190 | June 4, 2021 | May 31, 2026 | JAGANNATH, CHINNASWAMY | reporter.nih.gov |
| Human antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,799,861 | September 15, 2020 | August 31, 2025 | DIAMOND, MICHAEL S | reporter.nih.gov |
| Creating high-resolution, epitope-focused vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,794,402 | September 30, 2020 | July 31, 2025 | KIM, PETER S | reporter.nih.gov |
| Unmasking the roles of viral glycoproteins in oral transmission of KSHV | NIH | National Cancer Institute | 2021 to 2025 | $4,786,354 | September 1, 2021 | August 31, 2026 | OGEMBO, JAVIER GORDON | reporter.nih.gov |
| Identification of Metabolic and Immune Deficits in the Aged Population and Their Restoration to Achieve Youthful Anti-Influenza Vaccine Responsiveness | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,757,817 | November 22, 2021 | October 31, 2026 | MARASCO, WAYNE A. | reporter.nih.gov |
| Durable HIV Vaccine Targeting Mucosal Epithelium | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,751,308 | August 1, 2022 | July 31, 2027 | GAUDUIN, MARIE-CLAIRE ELISABETH | reporter.nih.gov |
| Development of Non-Human Primate Models to Assess Immunological Mechanisms and Antigenic Targets of Protective Sporozoite (SPZ) Vaccines and Establish Superior Efficacy of Next Generation SPZ vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,717,265 | April 1, 2021 | March 31, 2027 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,706,565 | September 21, 2022 | April 30, 2027 | THAMMAVONGSA, VILASACK | reporter.nih.gov |
| Immunologic control of HIV-1 through combination bNAbs and biologics. | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $4,702,057 | July 5, 2019 | December 31, 2025 | CASKEY, MARINA | reporter.nih.gov |
| DEVELOPMENT OF SAPONIN DMLT ADJUVANT (SDA) | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $4,695,387 | September 30, 2023 | September 29, 2026 | NORTON, ELIZABETH | reporter.nih.gov |
| Leveraging novel pediatric SHIVs to identify biomarkers of prophylactic efficacy of bnAb against breast milk HIV transmission | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $4,686,370 | September 25, 2025 | August 31, 2029 | FOUDA AMOU OU, GENEVIEVE GINY | reporter.nih.gov |
| A Global Syphilis Vaccine Targeting Outer Membrane Proteins of Treponema pallidum | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $4,663,782 | April 22, 2024 | March 31, 2029 | MOODY, MICHAEL ANTHONY | reporter.nih.gov |
| Heritable immunization of the white-footed mouse reservoir of Lyme disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,657,626 | September 1, 2021 | August 31, 2026 | ESVELT, KEVIN | reporter.nih.gov |
| Population genotyping of the germline immunoglobulin repertoire in AIDS-designated rhesus macaque breeding colonies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,657,141 | May 1, 2021 | August 31, 2030 | BOSINGER, STEVEN EDWARD | reporter.nih.gov |
| DYNAMICS AND EVOLUTION OF IMMUNE RESPONSES TO INFLUENZA VIRUSES | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,647,135 | June 29, 2020 | May 31, 2026 | ANTIA, RUSTOM NOSHIR | reporter.nih.gov |
| Elicitation of HIV Broadly Neutralizing Antibodies from Engineered B cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,634,490 | July 1, 2021 | December 31, 2026 | VOSS, JAMES EVEN | reporter.nih.gov |
| MYCOBACTERIUM TUBERCULOSIS (MTB) QUALITY ASSESSMENT PROGRAM (TBQA) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,608,548 | January 1, 2023 | December 31, 2023 | COFFIN, JEANETTE | reporter.nih.gov |
| Development of the INI-4001 and INI-2002 adjuvants within the context of a vaccine to prevent Lyme disease. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $4,583,801 | September 30, 2018 | September 29, 2024 | EVANS, JAY | reporter.nih.gov |
| GVIRF2023 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,504,988 | August 23, 2018 | May 31, 2023 | FRIEDE, MARTIN | reporter.nih.gov |
| Cytotoxic T Cell Mediated Immunity to Chlamydia | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,482,401 | July 1, 1996 | July 31, 2026 | STARNBACH, MICHAEL N | reporter.nih.gov |
| Maximizing germinal centers and somatic hypermutation to HIV Env immunogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,431,323 | February 1, 2016 | January 31, 2026 | CROTTY, SHANE P | reporter.nih.gov |
| Vaccine and Treatment Evaluation Units: Wolbachia-Infected Aedes aegypti Mosquitos in Reducing Arboviral Infection Brazil | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,402,306 | February 4, 2020 | November 30, 2027 | ROUPHAEL, NADINE | reporter.nih.gov |
| Molecular Analysis and Lineage Tracing of Influenza-Specific, Lung-Resident Memory B Cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,398,832 | April 7, 2020 | March 31, 2027 | RANDALL, TROY D | reporter.nih.gov |
| Dissecting Polyclonal Sera to Reveal Correlates of Productive Immune Responses to HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,391,888 | March 16, 2018 | February 29, 2028 | WARD, ANDREW BARRETT | reporter.nih.gov |
| Breaking the Barrier to an HIV Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,382,000 | September 30, 2022 | July 31, 2027 | SAWYER, SARA | reporter.nih.gov |
| An oral vaccine against Chlamydia trachomatis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $4,358,977 | April 19, 2024 | March 31, 2029 | ZHONG, GUANGMING | reporter.nih.gov |
| Optimizing glycan shield coverage, germline B cell receptor binding and epitope diversity of V2-apex targeted HIV-1 Env immunogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,308,687 | September 19, 2019 | August 31, 2029 | HAHN, BEATRICE H | reporter.nih.gov |
| VACCINES ADJUVANT DEVELOPMENT PROGRAM IN INFECTIOUS AND IMMUNE MEDIATED DISEASES | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $4,300,145 | September 30, 2023 | September 29, 2026 | DOWLING, DAVID JAMES | reporter.nih.gov |
| PROJECT MANAGEMENT SUPPORT FOR COMMUNITY ENGAGEMENT ON TRANS-NIH THERAPEUTICS AND VACCINE TRIALS | NIH | National Heart, Lung, and Blood Institute | 2021 | $4,297,649 | July 29, 2020 | January 28, 2021 | SHINGLEDECKER, DANIEL | reporter.nih.gov |
| KSHV Subunit Vaccine Candidates to Elicit Potent Humoral Immune Reponses against KSHV Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,284,115 | March 22, 2021 | February 28, 2027 | OGEMBO, JAVIER GORDON | reporter.nih.gov |
| Combining germline-targeting, B cell immunofocusing and Env-Ab co-evolution strategies to induce HIV Envelope V2-apex broadly neutralizing antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,257,922 | April 1, 2021 | June 30, 2023 | ANDRABI, RAIEES AHMAD | reporter.nih.gov |
| Targeting HIV reservoirs in children with HIVIS DNA and MVA-CMDR vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,251,563 | February 1, 2018 | February 28, 2026 | ROBB, MERLIN L | reporter.nih.gov |
| Preventing TB with intravenous BCG in SIV-infected macaques | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,248,442 | May 5, 2021 | April 30, 2026 | SCANGA, CHARLES A. | reporter.nih.gov |
| Influenza pathogenesis in pregnancy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,248,239 | June 14, 2021 | May 31, 2027 | ADAMS WALDORF, KRISTINA M. | reporter.nih.gov |
| The Role of Lipid-specific T cells in Mediating Protection Against M. tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,208,331 | June 1, 2020 | July 31, 2030 | SESHADRI, CHETAN | reporter.nih.gov |
| Antibody-based therapy for fentanyl-related opioid use disorder | NIH | National Institute on Drug Abuse | 2023 | $4,202,550 | September 30, 2023 | August 31, 2025 | DESAI, RAJEEV INDRAJIT | reporter.nih.gov |
| Imposing order on the family of ubiquitin-conjugating (E2) enzymes through intracellular perturbation with nanobodies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,159,500 | September 30, 2019 | July 31, 2024 | PLOEGH, HIDDE L. | reporter.nih.gov |
| Role of Inducible Bronchus Associated Lymphoid Tissue in Latent Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $4,152,012 | February 1, 2023 | January 31, 2027 | KHADER, SHABAANA A. | reporter.nih.gov |
| Structure and Dynamics of the SARS-CoV-2 Spike Protein | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,142,443 | July 12, 2021 | June 30, 2027 | MOTHES, WALTHER H | reporter.nih.gov |
| Inducing HIV-1 NAb Breadth by Native Trimer Prime-Boost Vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,133,062 | March 1, 2011 | May 31, 2025 | BINLEY, JAMES M | reporter.nih.gov |
| Development of mRNA-platform vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,121,318 | January 21, 2021 | December 31, 2026 | DAMRON, FREDRICK HEATH | reporter.nih.gov |
| Integrating human and non-human primate data to understand the acquisition of pre-erythrocytic immunity in the face of previous malaria exposure | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,114,200 | February 10, 2022 | January 31, 2027 | WILDER, BRANDON KEITH | reporter.nih.gov |
| Development of an oral liver-targeted prime-and-trap malaria vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,104,491 | December 1, 2020 | November 30, 2026 | MURPHY, SEAN C | reporter.nih.gov |
| Neutralizing the GBS hemolytic lipid toxin | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,096,432 | June 16, 2022 | May 31, 2027 | RAJAGOPAL, LAKSHMI | reporter.nih.gov |
| A STINGing vaccine for TB | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,090,805 | June 1, 2020 | May 31, 2026 | BISHAI, WILLIAM RAMSES | reporter.nih.gov |
| Cytomegalovirus (CMV), the gut barrier and immune dysfunction in HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,077,185 | March 15, 2021 | February 28, 2027 | SHACKLETT, BARBARA L. | reporter.nih.gov |
| Mosquito SAMSP1 and SAMSP2 influence the initial stage of Plasmodium infection of mice | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,052,693 | April 14, 2021 | March 31, 2027 | FIKRIG, EROL | reporter.nih.gov |
| A high-efficiency, low-cost, single-use purification technology for therapeutic antibody manufacturing | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $4,049,312 | September 1, 2019 | January 31, 2026 | HOWELL, DAVID W. | reporter.nih.gov |
| Innovations in Functional B Cell Epitope Discovery for Lyme Disease | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $4,031,164 | September 16, 2024 | September 15, 2026 | MANTIS, NICHOLAS | reporter.nih.gov |
| Defining functional humoral correlates of immunity to guide vaccine design | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,023,233 | November 24, 2020 | October 31, 2025 | BATISTA, FACUNDO DAMIAN | reporter.nih.gov |
| Modeling the ecology of tissue-resident T cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,020,006 | August 19, 2020 | May 31, 2026 | YATES, ANDREW | reporter.nih.gov |
| Nucleoside-modified mRNA vaccine for prevention and treatment of genital herpes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,009,506 | April 15, 2019 | June 30, 2027 | FRIEDMAN, HARVEY MICHAEL | reporter.nih.gov |
| HIV-1 dynamics and evolution during trispecific broadly neutralizing antibody therapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,008,532 | April 8, 2021 | March 31, 2026 | TSIBRIS, ATHE M. | reporter.nih.gov |
| Rational Systemic Characterization and Selection of Adjuvants for HIV Vaccine Candidates (R-CASA) | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,983,710 | August 1, 2025 | July 31, 2026 | CHATTERJEE, ARNAB KUMAR | reporter.nih.gov |
| Selecting HA glycosylation for improved vaccine responses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,957,417 | June 9, 2021 | May 31, 2027 | ZAIA, JOSEPH | reporter.nih.gov |
| Novel therapeutic approaches to treatment of botulinum neurotoxin poisoning | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,954,829 | April 15, 2011 | June 30, 2027 | ICHTCHENKO, KONSTANTIN | reporter.nih.gov |
| World Reference Center for Emerging Viruses and Arboviruses (WRCEVA) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,949,988 | February 1, 2016 | March 24, 2025 | WEAVER, SCOTT C | reporter.nih.gov |
| ReMARk: A multi-level strategy to address disparities in rural HPV-related cancer prevention | NIH | National Cancer Institute | 2022 to 2025 | $3,944,859 | September 22, 2022 | August 31, 2028 | STARAS, STEPHANIE A S | reporter.nih.gov |
| Efficacy of immunization with 4C-MenB in preventing experimental urethral infection with Neisseria gonorrhoeae. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,925,773 | July 1, 2021 | April 30, 2027 | DUNCAN, JOSEPH A | reporter.nih.gov |
| A systems immunology approach for predicting poor responses to Hepatitis B vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,925,255 | September 17, 2021 | August 31, 2026 | HERATI, RAMIN | reporter.nih.gov |
| A systems immunology approach to evaluate malaria vaccine performance in endemic regions of Kenya | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,921,000 | February 1, 2022 | January 31, 2027 | MOORMANN, ANN M | reporter.nih.gov |
| Tracking the evolutionary trajectory of neutralizing antibodies following BG505 SOSIP immunization | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,907,608 | June 16, 2023 | May 31, 2027 | DERDEYN, CYNTHIA ANN | reporter.nih.gov |
| Development of multi-modal single-cell technology to dissect epitope specificity to HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,892,813 | June 26, 2015 | May 31, 2026 | BOSINGER, STEVEN EDWARD | reporter.nih.gov |
| Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,892,523 | August 20, 2021 | July 31, 2025 | AZOITEI, MIHAI LUCHIAN | reporter.nih.gov |
| Development of a recombinant protein vaccine for Chlamydia trachomatis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,885,058 | May 10, 2024 | March 31, 2029 | DARVILLE, TONI | reporter.nih.gov |
| Discovery of Adjuvants for mRNA Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,882,045 | September 30, 2025 | September 29, 2026 | CARSON, DENNIS | reporter.nih.gov |
| Development of a novel TB vaccine safer and more effective than BCG based on a precisely controlled replication-limited Mycobacterium tuberculosis engineered for optimal in vivo growth and clearance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,876,556 | March 15, 2021 | February 28, 2027 | HORWITZ, MARCUS AARON | reporter.nih.gov |
| Cellular and molecular programming of lung resident T cell memory | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,857,630 | May 1, 2020 | April 30, 2027 | KOHLMEIER, JACOB E | reporter.nih.gov |
| Developing broad-spectrum therapeutics against C. difficile toxins | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,852,231 | February 11, 2021 | January 31, 2027 | JIN, RONGSHENG | reporter.nih.gov |
| Mechanisms of protection against shigellosis in children | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,843,317 | June 9, 2022 | May 31, 2027 | PASETTI, MARCELA F | reporter.nih.gov |
| Identification of novel immunogenic proteins from Bordetella pertussis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,825,567 | June 9, 2021 | May 31, 2027 | DUBEY, PURNIMA | reporter.nih.gov |
| Immune Dysfunction in HIV+ Opioid Users | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,823,539 | April 15, 2020 | January 31, 2027 | PAHWA, SAVITA | reporter.nih.gov |
| Understanding Pandemic Evolution through Networked Data (UPEND) | NIH | National Institute of Mental Health | 2023 | $3,822,251 | April 15, 2023 | April 14, 2026 | CROWELL, TREVOR ADAM | reporter.nih.gov |
| Functional profiling of OSP-specific and other antibodies during shigella infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,818,268 | September 22, 2020 | August 31, 2030 | RYAN, EDWARD T. | reporter.nih.gov |
| Statistical Issues in AIDS Research | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,816,097 | September 30, 1989 | March 31, 2029 | HUGHES, JAMES P | reporter.nih.gov |
| Immune response to COVID-19 vaccine in HIV infected men and women | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,779,701 | September 23, 2021 | August 31, 2026 | RINALDO, CHARLES R | reporter.nih.gov |
| Role of ncRNA Surveillance Complex "RNA Exosome" in Class Switch Recombination and Somatic Hypermutation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,761,466 | May 7, 2012 | April 30, 2027 | BASU, UTTIYA | reporter.nih.gov |
| O-Specific Polysaccharide Responses and Cholera | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,758,033 | August 7, 2013 | March 31, 2030 | RYAN, EDWARD T. | reporter.nih.gov |
| Development of a novel adjuvant strategy enabled by modulation of the physical properties of fungal mannans | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,755,681 | September 17, 2021 | August 31, 2026 | ZANONI, IVAN | reporter.nih.gov |
| Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,749,095 | August 1, 2021 | May 31, 2027 | LUSTIGMAN, SARA | reporter.nih.gov |
| Immunity to Cryptosporidium | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,739,027 | January 1, 2020 | December 31, 2029 | HUNTER, CHRISTOPHER A | reporter.nih.gov |
| Heterosubtypic immunity to influenza virus mediated by MHC-E-restricted memory NK cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,727,019 | September 24, 2021 | August 31, 2027 | JOST, STEPHANIE | reporter.nih.gov |
| Discovery of Adjuvants that Direct T-cell Fates for Improved Safety and Efficacy in Vaccines Against Influenza and Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,714,524 | September 30, 2025 | September 29, 2026 | ESSER-KAHN, AARON | reporter.nih.gov |
| A Phase II Evaluation of the Safety and Protective Efficacy of the Live Attenuated Tetravalent Dengue Vaccine TetraVax-DV with Challenge by the Recombinant DENV-2 Virus in a Dengue Endemic Population | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $3,713,909 | August 21, 2019 | July 31, 2025 | KIRKPATRICK, BETH DIANE | reporter.nih.gov |
| "Corral and Kill" strategy for HIV eradication using MSC in an SIV model | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,712,736 | March 23, 2020 | February 28, 2030 | DANDEKAR, SATYA | reporter.nih.gov |
| Structure-based design of broad flavivirus immunogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,710,975 | September 24, 2021 | August 31, 2026 | LAI, JONATHAN R. | reporter.nih.gov |
| Production of cGMP Native Flexibly Linked HIV-1 Envelope Protein | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,709,483 | September 12, 2016 | March 31, 2028 | FOUTS, TIMOTHY | reporter.nih.gov |
| Functional B-cell Epitope Discovery for Arthropod-Borne Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,708,329 | September 16, 2024 | September 15, 2027 | reporter.nih.gov | |
| Flipped Germinal Centers | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,701,340 | September 17, 2021 | August 31, 2026 | WESEMANN, DUANE R. | reporter.nih.gov |
| Exploiting antibody catalysis for treating Cryptococcosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,699,200 | May 25, 2021 | April 30, 2027 | CASADEVALL, ARTURO | reporter.nih.gov |
| Nonhuman Primate Core Virology Laboratory for AIDS Vaccine Research and Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,695,898 | December 22, 2017 | December 14, 2024 | DENNY, THOMAS | reporter.nih.gov |
| Combined cytokine therapy for sustained HIV remission | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,695,050 | March 17, 2020 | February 28, 2026 | VELU, VIJAYAKUMAR | reporter.nih.gov |
| Mapping spatiotemporal dynamics during enterovirus infection across cells and tissues | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,677,462 | March 10, 2022 | February 28, 2027 | ANDINO, RAUL | reporter.nih.gov |
| Evaluation of Antibody Responses Elicited by Zika Vaccination in Flavivirus-naïve and -experienced Individuals | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,665,742 | April 13, 2021 | March 31, 2027 | KREBS, SHELLY J | reporter.nih.gov |
| Studying factors controlling cancer progression and immune recognition in mouse models | NIH | National Cancer Institute | 2022 to 2025 | $3,664,660 | September 20, 2022 | August 31, 2029 | JACKS, TYLER E. | reporter.nih.gov |
| Structure, Function and Mechanistic Analysis of LAG3 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,664,179 | January 8, 2019 | December 31, 2028 | VIGNALI, DARIO AA | reporter.nih.gov |
| Using immune complex vaccines to optimize antibody responses to HIV Env | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,657,831 | March 12, 2020 | February 28, 2027 | HIOE, CATARINA E | reporter.nih.gov |
| Modeling and design of complex RNA structures | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,656,040 | September 1, 2017 | July 31, 2027 | DAS, RHIJU | reporter.nih.gov |
| Family-focused vs. Drinker-focused Smartphone Interventions to Reduce Drinking-related Consequences of COVID-19 | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2024 | $3,648,087 | September 25, 2021 | August 31, 2025 | GUSTAFSON, DAVID H | reporter.nih.gov |
| IND enabling CMC/safety/toxicology studies, submission of IND and pilot Phase 1 clinical trial with PV-1950R vaccine for Lewy Body Dementia (LBD) | NIH | National Institute on Aging | 2024 to 2025 | $3,640,661 | June 5, 2024 | May 31, 2029 | AGADJANYAN, MICHAEL G | reporter.nih.gov |
| Understanding Immune Evasion by HIV-1 Repliclones | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,617,103 | June 10, 2021 | May 31, 2027 | HALVAS, ELIAS K. | reporter.nih.gov |
| Hyaluronidase mediated GBS Disease | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,613,118 | July 14, 2025 | June 30, 2029 | RAJAGOPAL, LAKSHMI | reporter.nih.gov |
| Optimizing AAV delivery of bNAbs for HIV prevention | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,607,044 | November 24, 2021 | October 31, 2026 | GARDNER, MATTHEW RYAN | reporter.nih.gov |
| DEVELOPMENT OF A VACCINE CANDIDATE FOR DRUG-RESISTANT FUNGAL INFECTIONS | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,605,418 | September 30, 2025 | June 1, 2030 | NABORS, GARY | reporter.nih.gov |
| Development of a Replicon RNA-based Vaccine against Dengue and Zika | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,590,945 | June 1, 2021 | May 31, 2026 | SHRESTA, SUJAN | reporter.nih.gov |
| Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal | NIH | National Cancer Institute | 2021 to 2025 | $3,585,446 | July 1, 2010 | June 30, 2027 | NAKAGAWA, MAYUMI | reporter.nih.gov |
| Mechanisms of B cell responses to particulate antigens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,582,696 | July 1, 2021 | June 30, 2027 | CHENG, WEI | reporter.nih.gov |
| Structure-Guided Design of Broadly Neutralizing Lassa Virus BiSpecific Antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,575,135 | December 24, 2018 | November 30, 2024 | BRANCO, LUIS MANUEL | reporter.nih.gov |
| Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine Components | NIH | National Institute on Drug Abuse | 2023 | $3,569,552 | September 15, 2018 | March 31, 2028 | COMER, SANDRA D | reporter.nih.gov |
| PERSISTENCE OF IMMUNE RESPONSES TO THE RECOMBINANT ZOSTER VACCINE IN IMMUNE COMPROMISED HOSTS WITH END-STAGE RENAL DISEASE WITH AND WITHOUT KIDNEY TRANSPLANTATION | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,559,912 | March 6, 2019 | February 28, 2029 | WEINBERG, ADRIANA | reporter.nih.gov |
| Transforming HIV vaccine design with a hybrid technology that leverages features of mRNA and protein nanoparticle platforms | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,559,750 | September 26, 2025 | August 31, 2029 | HOFFMANN, MAGNUS ADRIAN GERO | reporter.nih.gov |
| Assessing the effects of oral pre-exposure prophylaxis on pharmacokinetics of monoclonal and vaccine-induced antibodies among women vulnerable to HIV-1 | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,554,273 | September 12, 2025 | August 31, 2029 | HUANG, YUNDA | reporter.nih.gov |
| Chronic Wasting Disease Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,544,335 | July 8, 2021 | June 30, 2027 | MATHIASON, CANDACE K. | reporter.nih.gov |
| The generation and protective function of lung tissue resident memory T cells following SARS-CoV-2 infection or vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,543,436 | March 1, 2022 | February 28, 2027 | TEIJARO, JOHN ROSS | reporter.nih.gov |
| Adjuvant Development Program in the context of vaccines to protect against Y. pestis and Shigella. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $3,532,934 | September 30, 2018 | September 29, 2023 | ERNST, ROBERT | reporter.nih.gov |
| Genetic, structural and functional profiling of the human antibody response to arenavirus infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,529,436 | August 22, 2022 | July 31, 2027 | BRINEY, BRYAN | reporter.nih.gov |
| Task A78: Mouse and Guinea Pig Models for Cytomegalovirus and Herpes Simplex Vviruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,527,311 | November 4, 2022 | November 3, 2024 | MADDOX, GRANT | reporter.nih.gov |
| Development of anti-LPS therapeutic antibodies for the treatment of Pseudomonas aeruginosa infections | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,521,872 | August 1, 2024 | July 31, 2029 | BARBIER, MARIETTE | reporter.nih.gov |
| Combination nanovaccine-based immunization against influenza virus in the aged: immunity and protection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,518,508 | February 16, 2021 | January 31, 2027 | KOHUT, MARIAN L | reporter.nih.gov |
| Antibody dependent cellular cytotoxicity and HIV-1 mother to child transmission | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,515,485 | September 19, 2022 | July 31, 2027 | SAGAR, MANISH | reporter.nih.gov |
| An ethnically diverse genomic reference resource for the human heavy and light chain immunoglobulin loci | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,511,108 | July 23, 2018 | August 31, 2027 | WATSON, COREY TAYLOR | reporter.nih.gov |
| Capsular serotype in group B Streptococcus colonization and disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,507,212 | June 8, 2021 | May 31, 2026 | RATNER, ADAM JONATHAN | reporter.nih.gov |
| Harnessing Highly Networked HLA-E-Restricted CTL Epitopes to Achieve a Broadly Effective HIV Cure | NIH | National Institute on Drug Abuse | 2023 to 2025 | $3,507,000 | April 1, 2023 | February 29, 2028 | GAIHA, GAURAV DAS | reporter.nih.gov |
| Inducing durable, protective immune memory against malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,488,192 | January 16, 2019 | December 31, 2023 | KAPPE, STEFAN HI | reporter.nih.gov |
| Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,483,730 | September 1, 2023 | August 31, 2028 | ROSEN, DAVID A. | reporter.nih.gov |
| Combination Adjuvants to Program Durable Immunity to Respiratory Viral and Fungal Pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,479,164 | February 17, 2016 | April 30, 2027 | SURESH, MARULASIDDAPPA | reporter.nih.gov |
| Evaluation of Memory Responses and Biomarkers from a Phase IEnterotoxigenic Escherichia coli (ETEC) Intramuscular SubunitVaccine with dmLT Adjuvant | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,467,638 | September 24, 2021 | August 31, 2026 | NORTON, ELIZABETH B | reporter.nih.gov |
| A Vaccine for Lymphatic Filariasis, LFGuard™ | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,448,456 | March 1, 2019 | November 30, 2027 | CARTER, DARRICK ALBERT | reporter.nih.gov |
| Development of MecVax, a Cross Protective Subunit Vaccine for ETEC | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,440,502 | June 1, 2023 | May 31, 2028 | ZHANG, WEIPING | reporter.nih.gov |
| Mechanistic Studies of Combination Adjuvants to Target B Cells in Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,438,006 | April 23, 2021 | March 31, 2027 | TEYTON, LUC | reporter.nih.gov |
| Reducing Latent Viral Reservoirs in Infant Macaques | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $3,436,436 | August 1, 2014 | June 30, 2025 | HAIGWOOD, NANCY L | reporter.nih.gov |
| Unraveling yellow fever 17D vaccine attenuation: The role of type I interferon and innate immunity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,421,854 | February 15, 2016 | July 31, 2027 | RICE, CHARLES M | reporter.nih.gov |
| A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-RANGING STUDY TO COMPARE THE SAFETY AND EFFICACY OF 3 DOSE LEVELS OF AV-1 IN HEALTHY ADULTS CHALLENGED WITH A CONTROLLED HUMAN INFECTION S | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $3,418,636 | August 23, 2023 | July 22, 2025 | DURBIN, ANNA PALMER | reporter.nih.gov |
| Sex and Age Differences in Immunity to Influenza (SADII) | NIH | National Institute on Aging | 2021 to 2022 | $3,417,361 | September 30, 2018 | May 31, 2023 | KLEIN, SABRA L. | reporter.nih.gov |
| Structural characterization of Fab-dimerized glycan-reactive antibodies that neutralize HIV-1 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,416,984 | September 17, 2021 | August 31, 2026 | ACHARYA, PRIYAMVADA | reporter.nih.gov |
| Development of a monoclonal antibody to reverse overdose from fentanyl and its analogs: from manufacturing to clinical trials | NIH | National Institute on Drug Abuse | 2025 | $3,410,308 | September 30, 2022 | July 31, 2028 | PRAVETONI, MARCO | reporter.nih.gov |
| Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,410,042 | February 21, 2019 | January 31, 2025 | PERLIN, DAVID S | reporter.nih.gov |
| Toward a universal influenza virus vaccine based on live attenuated NS1-deleted influenza viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,407,387 | January 7, 2019 | December 31, 2023 | GARCIA-SASTRE, ADOLFO | reporter.nih.gov |
| Immunobiology of Influenza Virus-related Critical Illness in Young Hosts | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,406,427 | September 18, 2020 | August 31, 2025 | RANDOLPH, ADRIENNE G | reporter.nih.gov |
| Structure and function of the Plasmodium myosin XIV-actin glideosome. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,384,780 | May 11, 2017 | June 30, 2027 | TRYBUS, KATHLEEN M | reporter.nih.gov |
| Community-Centered Interventions for Improved Vaccine Uptake for COVID (CIVIC) | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2025 | $3,378,034 | April 26, 2021 | May 9, 2025 | MARSH, ERICA E | reporter.nih.gov |
| Comparison of High Dose vs. Standard Dose Influenza Vaccines in Lung Allograft Recipients | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,375,497 | February 18, 2022 | January 31, 2027 | HALASA, NATASHA BASSAM | reporter.nih.gov |
| Structure, antigenicity, and function of HCMV fusogen gB | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,357,889 | June 8, 2021 | May 31, 2027 | HELDWEIN, EKATERINA | reporter.nih.gov |
| Targeting Clostridioides difficile with microbiome-sparing, resistant-proof anti-toxins | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,343,705 | April 1, 2021 | March 31, 2026 | SCHRAMM, VERN L. | reporter.nih.gov |
| Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,343,171 | January 9, 2019 | December 31, 2024 | IBRAHIM, ASHRAF S. | reporter.nih.gov |
| Development of an mRNA-Based Therapeutic HIV/AIDS Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,336,113 | March 5, 2020 | February 28, 2026 | OKOYE, AFAMEFUNA | reporter.nih.gov |
| Using parenteral combination adjuvants to induce pan-mucosal cellular and humoral immunity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,332,631 | June 21, 2022 | May 31, 2027 | MCLACHLAN, JAMES B | reporter.nih.gov |
| Micro-Particle Delivery of a Potent Intracellular Adjuvant for a Universal Flu Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,332,208 | December 14, 2018 | November 30, 2024 | TING, JENNY P | reporter.nih.gov |
| Cancer Immune-Interception for Lynch Syndrome | NIH | National Cancer Institute | 2021 to 2025 | $3,326,163 | September 21, 2021 | August 31, 2026 | VILAR SANCHEZ, EDUARDO | reporter.nih.gov |
| M. tuberculosis exosome detection for pediatric TB diagnosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,323,600 | June 1, 2025 | May 31, 2027 | LACOURSE, SYLVIA | reporter.nih.gov |
| Innate Immunity Stimulation Effects on Biomarkers, Cognition, and the Vascular Amyloid Proteome in a Squirrel Monkey Model of Sporadic CAA | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $3,321,272 | July 15, 2022 | June 30, 2027 | SCHOLTZOVA, HENRIETA | reporter.nih.gov |
| ARIA Pathophysiology Characterized by in vivo Neuroimaging, Plasma Biomarkers and Post-Mortem Proteomics | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $3,310,951 | June 4, 2025 | May 31, 2027 | WISNIEWSKI, THOMAS M | reporter.nih.gov |
| Vaccination with invariant MHC-II-linked accessory antigens for protection from HIV infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,308,638 | September 23, 2020 | August 31, 2025 | VEAZEY, RONALD S. | reporter.nih.gov |
| The uptake and real-world effectiveness of emerging respiratory syncytial virus maternal vaccines and monoclonal antibodies on short- and long-term respiratory morbidities | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,304,164 | August 11, 2025 | July 31, 2029 | WU, PINGSHENG | reporter.nih.gov |
| Trypanosome Transmission Biology in Tsetse | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,303,729 | December 17, 2021 | November 30, 2026 | AKSOY, SERAP | reporter.nih.gov |
| Multimodal PET-CT imaging of SIVmac239 dynamics post-ART interruption | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,302,677 | July 21, 2025 | June 30, 2029 | OKOYE, AFAMEFUNA | reporter.nih.gov |
| Longitudinal study of health outcomes and mitigating factors in the aftermath of the COVID pandemic | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,300,853 | September 21, 2021 | July 31, 2027 | MOHANAN, MANOJ | reporter.nih.gov |
| SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,300,000 | August 17, 2023 | July 31, 2026 | ALPERT, MICHAEL DAVID | reporter.nih.gov |
| Lipid-mediated fungal pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,299,415 | July 1, 2016 | August 31, 2027 | DEL POETA, MAURIZIO | reporter.nih.gov |
| Development of 4-(aroylamino)piperidine-based entry inhibitors as anti-influenza therapeutics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,297,972 | April 2, 2021 | April 30, 2026 | RONG, LIJUN | reporter.nih.gov |
| Development of a universal DISC vaccine strategy against congenital cytomegalovirus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,297,927 | April 7, 2021 | March 31, 2027 | MCGREGOR, ALISTAIR | reporter.nih.gov |
| Brief digital intervention to increase COVID-19 vaccination among individuals with anxiety or depression | NIH | National Institute of Mental Health | 2022 | $3,296,734 | September 1, 2022 | March 11, 2025 | NASH, DENIS | reporter.nih.gov |
| Comparison of High vs. Standard Dose Influenza Vaccines in Adult Solid Organ Transplant Recipients | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,293,620 | September 1, 2020 | June 30, 2025 | HALASA, NATASHA BASSAM | reporter.nih.gov |
| Clearance and In Vivo Detection of Tau Pathology | NIH | National Institute on Aging | 2021 to 2025 | $3,293,211 | August 1, 2008 | April 30, 2028 | SIGURDSSON, EINAR M | reporter.nih.gov |
| Examining IgG4 sialylation as a gain of function post-translation modification in IgG4-related diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,291,872 | July 1, 2020 | June 30, 2025 | ANTHONY, ROBERT MCCULLOUGH | reporter.nih.gov |
| B cell Epitope Discovery and Mechanisms of Antibody Protection for Enterovirus and Bunyavirus Entry Proteins | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,291,808 | September 16, 2024 | September 15, 2026 | reporter.nih.gov | |
| Once Bitten: Acquisition of Malaria Adaptive Immunity (OBAMA - Immunity) | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,285,014 | July 1, 2025 | June 30, 2028 | PRUDHOMMEOMEARA, WENDY | reporter.nih.gov |
| Natural killer cell regulation of the germinal center HIV neutralizing antibody response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,284,070 | December 1, 2019 | November 30, 2025 | BRADLEY, TODD CHRISTOPHER | reporter.nih.gov |
| Palliative Care Research Cooperative Group (PCRC): Refinement and Expansion | NIH | National Institute of Nursing Research | 2021 to 2022 | $3,268,072 | September 28, 2013 | June 30, 2023 | KUTNER, JEAN S | reporter.nih.gov |
| Advanced Development of a Combined Shigella-ETEC Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,267,570 | June 9, 2023 | May 31, 2028 | BARRY, EILEEN M. | reporter.nih.gov |
| Pathogenic low affinity CD8 T cells in malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,264,359 | September 17, 2021 | August 31, 2026 | LAMB, TRACEY JANE | reporter.nih.gov |
| Designing HIV-1 envelope immunogens to maximize neutralization breadth through use of multiple founder envelope antigens | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,259,509 | June 20, 2023 | May 31, 2027 | BOLTON, DIANE L. | reporter.nih.gov |
| Programming Durable Immune Responses To Vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,255,877 | December 18, 2018 | December 31, 2028 | ELLEBEDY, ALI HASSAN | reporter.nih.gov |
| Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer | NIH | National Cancer Institute | 2022 to 2025 | $3,252,105 | April 1, 2022 | August 31, 2027 | POWELL, DANIEL J. | reporter.nih.gov |
| Engineering the Skin Immune System to Induce Systemic Immune Responses | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $3,251,899 | March 4, 2021 | January 31, 2027 | FALO, LOUIS D | reporter.nih.gov |
| Glycoengineering eCD4-Ig | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,249,324 | March 9, 2022 | February 28, 2025 | ALPERT, MICHAEL DAVID | reporter.nih.gov |
| Vaccine-mediated cross-alphavirus protection for a live attenuated FDA licensed chikungunya virus vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,248,576 | July 25, 2025 | June 30, 2029 | COFFEY, LARK L | reporter.nih.gov |
| Human Monoclonal Antibodies for Encephalitic Alphaviruses | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,248,015 | July 20, 2022 | June 30, 2027 | CROWE, JAMES E | reporter.nih.gov |
| Escape of maternal plasma broadly neutralizing antibody as a mechanism of mother to child HIV transmission | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,247,236 | September 1, 2021 | August 31, 2025 | PERMAR, SALLIE R. | reporter.nih.gov |
| Combining germline-targeting, B cell immunofocusing and Env-Ab coevolution strategies to induce HIV Envelope V2-apex broadly neutralizing antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,245,040 | April 1, 2021 | May 31, 2027 | ANDRABI, RAIEES AHMAD | reporter.nih.gov |
| Evolution of T cell immunity in blood and tissues over childhood | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,243,813 | March 16, 2022 | February 28, 2027 | FARBER, DONNA L. | reporter.nih.gov |
| A novel Lyme disease vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,240,479 | June 7, 2022 | May 31, 2027 | FIKRIG, EROL | reporter.nih.gov |
| Novel nanoparticulate adjuvants to enhance HIV-1 Env specific mucosal antibody responses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,234,356 | July 3, 2019 | June 30, 2025 | KASTURI, SUDHIR PAI | reporter.nih.gov |
| Genetic and Structural Basis for Virus Neutralization of Paramyxoviruses | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,230,785 | September 16, 2024 | September 15, 2027 | reporter.nih.gov | |
| An experimentally-refined, dynamic gene regulatory network model of T-cell memory | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,230,746 | March 8, 2021 | February 28, 2027 | BARSKI, ARTEM | reporter.nih.gov |
| Novel Methods to Inform HIV/TB Clinical Trial Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,228,180 | September 1, 2011 | August 31, 2025 | REDDY, KRISHNA P | reporter.nih.gov |
| A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,217,894 | August 4, 2023 | July 31, 2027 | SHOEMAKER, CHARLES BIX | reporter.nih.gov |
| Reverse Vaccinology in SHIV Infected Macaques as a Molecular Guide for HIV-1 Vaccine Design | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,216,371 | March 11, 2021 | February 28, 2026 | SHAW, GEORGE M | reporter.nih.gov |
| Viper Resource Grant at Texas A&M University-Kingsville | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $3,214,960 | April 15, 2003 | April 30, 2029 | SANCHEZ, ELDA E. | reporter.nih.gov |
| Drivers of strain-specific and strain-transcendent antimalarial immunity in childhood | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,209,021 | June 17, 2020 | May 31, 2026 | GREENHOUSE, BRYAN R | reporter.nih.gov |
| B cell clonal selection in gut-associated germinal centers | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,203,164 | September 17, 2020 | August 31, 2025 | VICTORA, GABRIEL D | reporter.nih.gov |
| Identification of Novel Syk/Raf-1 Mediated CLR Ligands as Vaccine Adjuvants | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,198,798 | September 30, 2025 | September 29, 2026 | EVANS, JAY | reporter.nih.gov |
| Development of a Chimeric Syphilis Vaccine Candidate to Combat Local, Disseminated and Congenital Syphilis Infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,194,893 | April 15, 2024 | March 31, 2029 | CAMERON, CAROLINE E | reporter.nih.gov |
| Synthesis and Evaluation of Carbohydrate Vaccine Adjuvants | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,192,190 | June 10, 2022 | May 31, 2027 | NGUYEN, HIEN M | reporter.nih.gov |
| Host Responses to the Pore-Forming Toxin Listeriolysin O | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,191,205 | April 1, 2021 | March 31, 2027 | SEVEAU, STEPHANIE M M | reporter.nih.gov |
| To Develop and Manufacture an Inactivated SARS-CoV-2 Vaccine Using Blood Pathogen Reduction Technology | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,181,780 | September 1, 2020 | April 30, 2026 | GOODRICH, RAYMOND | reporter.nih.gov |
| Defining the role of T cell help in germinal centers by intercellular enzymatic labeling | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,176,273 | September 21, 2022 | July 31, 2027 | VICTORA, GABRIEL D | reporter.nih.gov |
| Development of human adaptive immunity to Staphylococcus aureus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,170,541 | March 5, 2021 | February 28, 2027 | BUBECK WARDENBURG, JULIANE | reporter.nih.gov |
| Rational development of a vaccine against tick-borne rickettsioses | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,166,318 | August 1, 2022 | July 31, 2027 | FANG, RONG MEGAN | reporter.nih.gov |
| Mechanistic and functional dissection of inflammaging in Down syndrome | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,165,277 | September 1, 2022 | August 31, 2027 | KHOR, BERNARD | reporter.nih.gov |
| Transmission dynamics and fitness of reemerging St. Louis encephalitis virus in mosquito vectors and West Nile virus naïve and immune avian reservoirs | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,161,373 | July 22, 2025 | June 30, 2029 | COFFEY, LARK L | reporter.nih.gov |
| Early life B cell responses and inflammation following SARS-CoV-2 infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,160,521 | September 17, 2021 | August 31, 2026 | FOUDA AMOU OU, GENEVIEVE GINY | reporter.nih.gov |
| Epitope-focused vaccine strategies against Zika virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $3,153,813 | August 1, 2018 | July 31, 2023 | NUSSENZWEIG, MICHEL C | reporter.nih.gov |
| System Biological Analyses of Innate and Adaptive Responses to Vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $3,147,703 | March 1, 2021 | June 30, 2023 | PULENDRAN, BALI | reporter.nih.gov |
| Development of a Multi-species Vaccine for Prevention of Bacterial Otitis Media | NIH | National Institute on Deafness and Other Communication Disorders | 2022 to 2024 | $3,145,522 | January 1, 2022 | December 31, 2025 | MCOSKER, CHARLES C. | reporter.nih.gov |
| Analysis of a novel Crimean-Congo hemorrhagic fever vaccine and its mechanism of protection in rodent models | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,145,040 | August 25, 2022 | July 31, 2026 | SCHNELL, MATTHIAS JOHANNES | reporter.nih.gov |
| CD4+ T cells and neoantigens in melanoma immunotherapy. | NIH | National Cancer Institute | 2021 to 2025 | $3,143,740 | December 1, 2020 | November 30, 2026 | WANG, RONGFU | reporter.nih.gov |
| Coordinated studies in monkeys and humans to assess the immunological impact of rectal Chlamydia trachomatis infection on protection against genital infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,139,154 | April 1, 2023 | March 31, 2028 | VOJTECH, LUCIA N | reporter.nih.gov |
| Maternal Antibody-Mediated Enhancement of Dengue Pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,138,902 | March 5, 2021 | February 28, 2026 | SHRESTA, SUJAN | reporter.nih.gov |
| Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,135,970 | February 1, 2019 | January 31, 2029 | DIEHL, SEAN A. | reporter.nih.gov |
| Shigella Conjugate Vaccine (SCV4) Development, Characterization, and Pre-clinical Evaluation | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,134,727 | June 23, 2023 | May 31, 2028 | RYAN, EDWARD T. | reporter.nih.gov |
| B-Cell Epitope Discovery and Mechanisms of Antibody Protection for ZIKV, MARV, VEEV Envelope Proteins | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,133,973 | September 16, 2019 | September 15, 2024 | DORANZ, BENJAMIN | reporter.nih.gov |
| CONTROL AND ACTIVATION OF THE TUMOR NECROSIS FACTOR RECEPTORS | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,130,533 | February 1, 2020 | June 30, 2025 | WAGNER, GERHARD | reporter.nih.gov |
| Cervicovaginal microbiome, mucosal immunity, and pathogen factors that contribute to spontaneous clearance of Chlamydia trachomatis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,127,515 | June 1, 2022 | May 31, 2027 | BROTMAN, REBECCA M. | reporter.nih.gov |
| Intestinal microbiota-mediated rotavirus vaccine failure | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,123,686 | September 19, 2022 | July 31, 2027 | GEWIRTZ, ANDREW T | reporter.nih.gov |
| Mechanisms of Enhanced Neutralizing Antibody Responses to Rhinovirus C | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,122,828 | March 20, 2020 | February 28, 2026 | BOCHKOV, YURY A | reporter.nih.gov |
| Structure and immunogenicity of novel trimeric HIV-1 Env immunogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,119,393 | September 19, 2019 | August 31, 2025 | KONG, XIANGPENG | reporter.nih.gov |
| Targeted immune therapies in heart transplantation | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $3,118,293 | February 1, 2023 | January 31, 2026 | ABDI, REZA | reporter.nih.gov |
| Structural interrogation of vaccine- and infection-induced B cell responses | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,116,277 | February 22, 2022 | January 31, 2027 | BAJIC, GORAN | reporter.nih.gov |
| Molecular and structural characterization of broadly neutralizing anti-HCV antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,115,747 | February 15, 2023 | January 31, 2028 | BAILEY, JUSTIN RICHARD | reporter.nih.gov |
| Preclinical studies of a Cryptococcus vaccine for AIDS patients | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,109,260 | February 11, 2016 | January 31, 2027 | LODGE, JENNIFER K. | reporter.nih.gov |
| Universal room temperature stable influenza nanovaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,103,165 | January 24, 2019 | December 31, 2024 | NARASIMHAN, BALAJI | reporter.nih.gov |
| Uncovering latent factors underlying weak and robust responses to influenza vaccine in healthy and obese older adults | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,095,170 | July 13, 2022 | June 30, 2027 | ALCORN, JOHN F | reporter.nih.gov |
| Conjugate vaccines for prevention and treatment of cryptococcosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,088,569 | March 2, 2020 | February 28, 2026 | CASADEVALL, ARTURO | reporter.nih.gov |
| The impact of T cell selection on vaccine durability | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,085,906 | September 24, 2021 | August 31, 2027 | SU, LAURA | reporter.nih.gov |
| Molecular Mechanisms of Adjuvant Triplet Combinations | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,084,459 | March 12, 2021 | February 28, 2026 | CHEVRIER, NICOLAS | reporter.nih.gov |
| EXTENSION OF ESCUDDO FOLLOW-UP FROM FIVE YEARS TO 7.5 YEARS (REFERRED TO AS ESCUDDO-7) | NIH | National Cancer Institute | 2025 | $3,083,060 | March 26, 2025 | September 15, 2025 | reporter.nih.gov | |
| Immunological characterization of rationally-designed vaccines against plague in mice and non-human primate models | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,082,735 | February 1, 2021 | July 31, 2026 | CHOPRA, ASHOK K | reporter.nih.gov |
| TCR-dependent and epigenetic mechanisms guiding influenza-specific CD4+ T cell responses in the lung | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,078,308 | August 1, 2025 | July 31, 2029 | HALE, JEFFREY SCOTT | reporter.nih.gov |
| Project 2VIDA! SARS-CoV-2 Vaccine Intervention Delivery for Adults in Southern California | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2025 | $3,077,210 | April 23, 2021 | January 31, 2027 | SKAATHUN, BRITT | reporter.nih.gov |
| Mechanisms of combined CD40/TLR adjuvant-elicited cellular immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,071,761 | March 25, 2021 | February 28, 2026 | KEDL, ROSS M | reporter.nih.gov |
| Rapid response for pandemics: single cell sequencing and deep learning to predict antibody sequences against an emerging antigen | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,071,572 | September 16, 2021 | August 31, 2025 | RAY, ANIMESH | reporter.nih.gov |
| Novel delivery platform and antigen design for an effective COVID-19 vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,066,236 | August 11, 2020 | July 31, 2027 | MITTAL, SURESH K | reporter.nih.gov |
| Translational studies of hookworm infection in Ghana | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,065,354 | February 22, 2022 | January 31, 2027 | CAPPELLO, MICHAEL | reporter.nih.gov |
| Mechanisms of Innate Immune Evasion by Mycobacterium Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,061,547 | January 1, 2017 | December 31, 2026 | PHILIPS, JENNIFER A | reporter.nih.gov |
| Leveraging population-based human data to uncover mechanisms connecting Alzheimer's disease and common infections and facilitate vaccines repurposing for AD prevention | NIH | National Institute on Aging | 2021 to 2025 | $3,052,023 | September 30, 2021 | June 30, 2027 | OUKRAINTSEVA, SVETLANA V. | reporter.nih.gov |
| Building the foundations of commensal vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,047,222 | September 23, 2022 | August 31, 2027 | FISCHBACH, MICHAEL ANDREW | reporter.nih.gov |
| HIV-1 vaccine-elicited antibodies target envelope glycans | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,044,804 | June 15, 2015 | July 31, 2025 | SAUNDERS, KEVIN O | reporter.nih.gov |
| Quantitative mapping of dynamic epigenetic states in rare and stimulated immune cells | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $3,043,595 | August 18, 2022 | July 31, 2025 | KEOGH, MICHAEL-CHRISTOPHER | reporter.nih.gov |
| Systems biological assessment of vaccination-induced protective immunity in African children | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,037,984 | February 1, 2022 | January 31, 2027 | PULENDRAN, BALI | reporter.nih.gov |
| Enhancing cytotoxic lymphocytes in a TB vaccine strategy | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,037,076 | February 25, 2022 | January 31, 2027 | FLYNN, JOANNE L. | reporter.nih.gov |
| GMP MANUFACTURE OF CLINICAL GRADE THERAPEUTIC VACCINE FOR THE TREATMENT OF PATIENTS WITH CHRONIC HBV | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $3,034,670 | June 5, 2018 | March 31, 2025 | NAKAAR, VALERIAN | reporter.nih.gov |
| Using Disadvantage Indices in Pandemic Vaccine Allocation and Beyond to Promote Health Opportunity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,031,954 | July 1, 2022 | June 30, 2027 | SCHMIDT, THOMAS HARALD | reporter.nih.gov |
| Structure-guided engineering to increase respiratory syncytial virus G protein immunogenicity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,030,788 | May 19, 2022 | April 30, 2027 | DUBOIS, REBECCA MICHELLE | reporter.nih.gov |
| Therapeutic vaccination to augment stringent response-specific T-cell immunity to MTB persisters | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,027,518 | March 17, 2020 | February 28, 2025 | KARAKOUSIS, PETROS C | reporter.nih.gov |
| Effect of natural and engineered variations on structure and biophysics of SARS-CoV-2 spike | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,026,517 | February 1, 2022 | January 31, 2027 | ACHARYA, PRIYAMVADA | reporter.nih.gov |
| MAb Passive Vaccination against Acinetobacter baumannii | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,021,383 | September 25, 2017 | August 31, 2027 | SPELLBERG, BRAD J | reporter.nih.gov |
| Understanding the mechanisms of antibody-mediated transcytosis of ZIKV within the placenta | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,021,123 | June 11, 2020 | May 31, 2026 | SUTHAR, MEHUL SHAMAL | reporter.nih.gov |
| Clonal Dynamics of the antibody response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,017,736 | January 1, 2017 | December 31, 2026 | VICTORA, GABRIEL D | reporter.nih.gov |
| Design of single-shot sequential immunization regimens for HIV using atomic layer deposition technology. | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,017,032 | August 8, 2025 | July 31, 2029 | IRVINE, DARRELL J | reporter.nih.gov |
| The role of Trained Immunity and Mitochondrial dysfunction on INnate immunity in children and adolescents aGing with PHIV (TIMING-PHIV) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,016,481 | March 21, 2022 | February 28, 2027 | FUNDERBURG, NICHOLAS T. | reporter.nih.gov |
| Respiratory Virus Vaccine and Adjuvant Exploration | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,000,000 | April 19, 2019 | March 31, 2025 | BARIC, RALPH S | reporter.nih.gov |
| A Unique Automated Bioreactor for Rearing Aseptic Mosquitoes from Larvae to Adults to Support Manufacture of Sanaria PfSPZ Products | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,000,000 | July 18, 2018 | March 31, 2025 | BILLINGSLEY, PETER F. | reporter.nih.gov |
| Development of a ZIKA viral pseudoinfectious virus as ZIKA vaccine candidate (STTR Phase II) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,000,000 | August 1, 2017 | March 31, 2026 | PANG, XIAOWU | reporter.nih.gov |
| DEVELOPMENT OF COVALENTLY BOUND HYALURONIC ACID AS AN ADJUVANT FOR MULTIVALENT LYME DISEASE VACCINE | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $2,999,999 | September 30, 2024 | September 29, 2027 | PETILLO, PETER A | reporter.nih.gov |
| eCD4-Ig for preventing and treating obstetric HIV infection | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $2,999,760 | August 13, 2020 | May 31, 2026 | MARTINS, MAURICIO DE AGUIAR | reporter.nih.gov |
| VESIVAX TLR7 FORMULA | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $2,999,352 | September 1, 2024 | August 31, 2027 | HO, SAMON | reporter.nih.gov |
| Universal Influenza A/B Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,998,889 | August 7, 2020 | April 30, 2026 | BAGLEY, KENNETH C | reporter.nih.gov |
| Vaccine Induced Immune-Inflammatory Response and Cardiovascular Risk | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,998,175 | April 1, 2021 | March 31, 2026 | CHENG, SUSAN | reporter.nih.gov |
| A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,998,001 | April 21, 2020 | March 31, 2027 | SIM, B. KIM LEE | reporter.nih.gov |
| Recombinant West Nile Virus Vaccine Adjuvanted with SLA-LSQ Optimize Formulation of VSA Adjuvant | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $2,997,218 | July 5, 2022 | July 5, 2025 | CLEMENTS, DAVID | reporter.nih.gov |
| Increasing Availability of Emulsion Adjuvants via Synthetic Biology | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $2,996,311 | August 30, 2022 | August 29, 2025 | KEMPINSKI, CHASE | reporter.nih.gov |
| Personal tumor neoantigens for immunity against chronic lymphocytic leukemia | NIH | National Cancer Institute | 2022 to 2025 | $2,996,021 | June 1, 2011 | January 31, 2027 | WU, CATHERINE JU-YING | reporter.nih.gov |
| Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,995,034 | July 14, 2022 | June 30, 2026 | MARATHI, UPENDRA | reporter.nih.gov |
| Progressing PfSPZ vaccines for malaria to licensure and commercialization | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,994,338 | April 14, 2023 | March 31, 2027 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| Live-attenuated Rift Valley fever vaccines: comparative mechanisms of trans-placental transmission and vaccine efficacy for developing fetuses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,993,583 | March 1, 2020 | February 28, 2027 | HARTMAN, AMY L | reporter.nih.gov |
| Novel vaccine strategies to induce V2 apex-directed broad neutralizing antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,993,032 | July 4, 2019 | June 30, 2025 | VERKOCZY, LAURENT KARL | reporter.nih.gov |
| Development of a Group B Streptococcus bioconjugate vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,991,364 | March 12, 2019 | May 31, 2027 | HARDING, CHRISTIAN | reporter.nih.gov |
| Research and Development to Establish a Small Animal Model as a Significant Resource of High-Value Single-Domain Antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,990,687 | March 1, 2018 | August 31, 2025 | KIRILOV, MILEN | reporter.nih.gov |
| Intranasal Vaccine Against Lyme Disease | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,988,409 | July 12, 2022 | June 30, 2026 | GOMES-SOLECKI, MARIA | reporter.nih.gov |
| Development of World's First Fully Human Broad Spectrum Anti-Snake Venom | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,987,953 | August 14, 2019 | July 31, 2026 | GLANVILLE, JACOB | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| PPD Development LP | Wilmington, NC | 3 | $685.1 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 52 | $652.8 million | 0 | $0 |
| Duke University | Durham, NC | 79 | $459.8 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 45 | $349.9 million | 0 | $0 |
| Fred Hutchinson Cancer Research Center | Seattle, WA | 35 | $290.8 million | 0 | $0 |
| Emory University | Atlanta, GA | 95 | $274.4 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 80 | $249.1 million | 0 | $0 |
| Scripps Research Institute, the | La Jolla, CA | 50 | $233.1 million | 0 | $0 |
| Family Health International | Durham, NC | 2 | $214.7 million | 0 | $0 |
| ST. Jude Children's Research Hospital | Memphis, TN | 12 | $165.1 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 56 | $143.3 million | 0 | $0 |
| Seattle Children's Hospital | Seattle, WA | 30 | $141.9 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 60 | $135.8 million | 0 | $0 |
| University of Washington | Seattle, WA | 64 | $134.3 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 58 | $117.8 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 37 | $117.1 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 60 | $101.3 million | 0 | $0 |
| Washington University | Saint Louis, MO | 79 | $100.7 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 59 | $100.2 million | 0 | $0 |
| University of Georgia Research Foundation Inc | Athens, GA | 28 | $97 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 55 | $95.4 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 37 | $93.9 million | 0 | $0 |
| Stanford University | Stanford, CA | 50 | $81 million | 0 | $0 |
| University of Chicago | Chicago, IL | 35 | $76.5 million | 0 | $0 |
| Yale University | New Haven, CT | 55 | $75.6 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 26 | $71.1 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 48 | $70.5 million | 0 | $0 |
| La Jolla Institute for Immunology | La Jolla, CA | 21 | $69.1 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 37 | $68.6 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 41 | $68 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 36 | $67.1 million | 0 | $0 |
| Tulane University of Louisiana | New Orleans, LA | 22 | $64 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 32 | $62.5 million | 0 | $0 |
| Harvard University D/b/a Harvard School of Public Health | Boston, MA | 13 | $60.9 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 19 | $60 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 28 | $58.5 million | 0 | $0 |
| Rockefeller University | New York, NY | 23 | $57 million | 0 | $0 |
| University of California at Davis | Davis, CA | 34 | $55.1 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 47 | $54.2 million | 0 | $0 |
| Technical Resources International, Inc. | Bethesda, MD | 2 | $52.4 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 22 | $52 million | 0 | $0 |
| Beth Israel Deaconess Medical Center | Boston, MA | 14 | $48.5 million | 0 | $0 |
| Fisher Bioservices, Inc. | Rockville, MD | 2 | $47.9 million | 0 | $0 |
| Advanced Bioscience Laboratories, Inc. | Kensington, MD | 7 | $47.2 million | 0 | $0 |
| Westat, Inc. | Bethesda, MD | 1 | $45.2 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 24 | $44.2 million | 0 | $0 |
| University of Texas Med BR Galveston | Galveston, TX | 30 | $41.7 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 39 | $41.5 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 37 | $40.7 million | 0 | $0 |
| Sanaria, Inc. | Rockville, MD | 19 | $39.2 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 22 | $37.1 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 29 | $37 million | 0 | $0 |
| University of Montana | Missoula, MT | 9 | $35.6 million | 0 | $0 |
| Ohio State University | Columbus, OH | 35 | $35.1 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 28 | $34.3 million | 0 | $0 |
| University of Rochester | Rochester, NY | 17 | $34.1 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 30 | $33.4 million | 0 | $0 |
| Fundacion Inciensa | San Jose | 2 | $32.6 million | 0 | $0 |
| Henry M. Jackson FDN for the Adv Mil/med | Bethesda, MD | 14 | $32.6 million | 0 | $0 |
| Dana-Farber Cancer Inst | Boston, MA | 20 | $30.4 million | 0 | $0 |
| University of Florida | Gainesville, FL | 25 | $30.2 million | 0 | $0 |
| Battelle Memorial Institute | Columbus, OH | 3 | $30.1 million | 0 | $0 |
| Saint Louis University | Saint Louis, MO | 10 | $29.7 million | 0 | $0 |
| University of TX MD Anderson Can CTR | Houston, TX | 17 | $29.1 million | 0 | $0 |
| Midwest Research Institute | Kansas City, MO | 3 | $29 million | 0 | $0 |
| Institute for Molecular Medicine | Huntington Beach, CA | 4 | $27.5 million | 0 | $0 |
| Massachusetts Institute of Technology | Cambridge, MA | 22 | $26.3 million | 0 | $0 |
| Wistar Institute | Philadelphia, PA | 10 | $26.1 million | 0 | $0 |
| University of California-Berkeley | Berkeley, CA | 12 | $26.1 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 8 | $25.6 million | 0 | $0 |
| Access to Advanced Health Institute | Seattle, WA | 4 | $25.1 million | 0 | $0 |
| Thomas Jefferson University | Philadelphia, PA | 14 | $24.9 million | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 15 | $24.1 million | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 11 | $23.9 million | 0 | $0 |
| Kaiser Foundation Research Institute | Oakland, CA | 8 | $23 million | 0 | $0 |
| University of Iowa | Iowa City, IA | 25 | $22.9 million | 0 | $0 |
| Digital Infuzion, Inc. | Rockville, MD | 2 | $22.8 million | 0 | $0 |
| Harvard Medical School | Boston, MA | 20 | $21.4 million | 0 | $0 |
| University of Illinois at Urbana-Champaign | Urbana, IL | 16 | $21.1 million | 0 | $0 |
| University of Miami School of Medicine | Coral Gables, FL | 12 | $21 million | 0 | $0 |
| New Mexico State University | Las Cruces, NM | 1 | $20.7 million | 0 | $0 |
| Banner Health | Phoenix, AZ | 1 | $20.4 million | 0 | $0 |
| University of Maryland, College Park | College Park, MD | 14 | $20 million | 0 | $0 |
| University of Missouri-Columbia | Columbia, MO | 16 | $19.6 million | 0 | $0 |
| University of Texas HLTH Sci CTR Houston | Houston, TX | 24 | $19.5 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 21 | $19.2 million | 0 | $0 |
| University of New Mexico Health Scis CTR | Albuquerque, NM | 15 | $19.1 million | 0 | $0 |
| International Aids Vaccine Initiative | New York, NY | 6 | $18.3 million | 0 | $0 |
| Georgia State University | Atlanta, GA | 14 | $18.1 million | 0 | $0 |
| SUNY at Buffalo | Amherst, NY | 15 | $18.1 million | 0 | $0 |
| HDT Bio Corporation | Seattle, WA | 10 | $18 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 19 | $17.8 million | 0 | $0 |
| University of Cape Town | Rondebosch | 4 | $17.4 million | 0 | $0 |
| University of Texas HLTH Science Center | San Antonio, TX | 13 | $17 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 12 | $16.2 million | 0 | $0 |
| Texas Biomedical Research Institute | San Antonio, TX | 11 | $16 million | 0 | $0 |
| University of Southern California | Los Angeles, CA | 11 | $15.6 million | 0 | $0 |
| Hackensack University Medical Center | Hackensack, NJ | 5 | $15.6 million | 0 | $0 |
| Colorado State University | Fort Collins, CO | 14 | $15.5 million | 0 | $0 |
| Asociacion Civil Impacta Salud Y Educacn | Lima | 1 | $15.5 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 1,664 | $1,618,107,029 | 0 | $0 |
| 2024 | 1,754 | $1,652,532,462 | 0 | $0 |
| 2023 | 1,812 | $1,761,134,134 | 0 | $0 |
| 2022 | 1,824 | $2,049,185,570 | 0 | $0 |
| 2021 | 1,818 | $2,352,108,313 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Change of Recipient Organization (Type 7 Parent Clinical Trial Optional) | PA-24-254 | NIH | July 12, 2027 | Not listed | Notice number printed on 24 awards here | |
| NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed) | PA-24-194 | NIH | May 7, 2027 | Not listed | Notice number printed on 8 awards here | |
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed) | PA-24-185 | NIH | May 7, 2027 | Not listed | Notice number printed on 3 awards here | |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) | PA-24-176 | NIH | May 7, 2027 | Not listed | Notice number printed on 2 awards here | |
| Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed) | PA-24-182 | NIH | May 8, 2027 | Not listed | Notice number printed on 2 awards here | |
| Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required) | PA-24-187 | NIH | May 7, 2027 | Not listed | Notice number printed on 1 award here | |
| NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed) | PA-25-080 | NIH | September 7, 2027 | Not listed | Notice number printed on 1 award here | |
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 2,402 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 2,402 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.855 | November 16, 2026 | $50,000 | Same assistance listing 93.855 as 2,402 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 2,402 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 2,402 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.855 | January 7, 2027 | Not listed | Same assistance listing 93.855 as 2,402 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 2,402 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 2,402 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 2,402 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 2,402 awards here |
| Precision and Systems Biology to Uncover the Link Between Chronic and Infectious Diseases | RFA-AI-28-014 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 2,402 awards here |
| Immune Tolerance Network (UM1 Clinical Trial Required) | RFA-AI-28-005 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 2,402 awards here |
| Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed) | RFA-AI-28-012 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 2,402 awards here |
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.